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ABSTRACT 
Regardless of progress in the therapy of AML, there is no long-term cure for about 
70% of AML patients. Leukemic stem cells seem to be an important key for the 
perpetuation of AML. Most currently used chemotherapeutic agents are not able to 
eliminate AML-LSCs. The combination of conventional therapies with AML-LSCs-
directed therapies may eventually lead to a cure for AML patients. For efficient 
targeting of AML-LSCs, identification of an appropriate cell surface marker 
preferentially expressed on AML-LSCs, but absent on normal tissue, especially on 
normal HSCs is essential. To date only a few potential target antigens have been 
defined but most of these target antigens are also expressed on normal 
hematopoietic stem cells or nonhematopoietic tissues. Recently expression of CD96 
(TACTILE) was reported on AML-LSCs, while only very low expression levels were 
found on normal HSCs. CD96 was also detected on the majority of AML blasts, in 
about 30% of AML patients. Therefore CD96 may be an excellent target antigen for 
therapeutic antibodies directed against AML stem cells and blasts. TH-111, a CD96 
mouse monoclonal antibody was previously generated in our lab. To reduce the 
immunogenicity of the mouse antibody for clinical use in humans, the V-regions of 
the CD96 mouse antibody TH-111 were isolated and a functional scFv was 
generated by phage display. The CD96-scFv retained the antigen specificity of the 
CD96 parental antibody. CD96-scFv was cloned into a human IgG1-Fc and 
subjected to ADCC using CD96-positive cells as target cells and human 
mononuclear effector cells. This mini-antibody mediated ADCC only modestly. To 
improve the anticancer efficacy of this antibody, CD96-scFv was affinity maturated by 
random mutagenesis through error-prone-PCR and mutated CD96-scFv with high 
binding affinity to CD96 was selected through phage display and stringent screening 
process. The mutated variant of scFv-based mini-antibody showed a 4-fold 
enhanced antigen binding affinity to CD96. Affinity maturated variant of the scFv was 
fused to a wild type IgG1-Fc or a variant with engineered/enhanced effector functions 
(IgG1-Fc-eng). The mini-antibody with affinity-maturated scFv and the engineered 
IgG1-Fc variant demonstrated the highest lytic capacity, suggesting that affinity to 
CD96 as well as efficient Fc receptor binding contributed to the observed effects. 
This recombinant antibody may be potentially useful in different clinical settings, 
including ex vivo purging of AML-LSCs from autologous stem cell preparations or for 
the targeting of AML-LSCs in vivo.  
 XIX 
ZUSAMMENFASSUNG  
Bei der akuten myeloischen Leukämie kann nur in ca. 30% der Fälle durch eine 
intensive Chemotherapie eine anhaltende Remission erreicht werden. Ein Grund für 
häufige Residive ist in der höheren Resistenz der AML-Stammzellen gegenüber 
Chemotherapeutika begründet. Daher erscheinen in Zukunft zielgerichtete Therapien 
aussichtsreich, die primär diese Leukämiestammzellen und auch  Leukämie Blasten 
als Zielzelle erkennen und effektiv eliminieren. Um die AML-Stammzellen 
zielgerichtet zu attackieren, ist es von entscheidender Bedeutung, Zielmoleküle zu 
identifizieren und zu validieren, die möglichst spezifisch zwischen entarteter Zielzelle 
und gesundem Gewebe differenzieren. Nur wenige geeignete Zielstrukturen auf 
AML-Stammzellen sind bisher beschrieben worden. Diese Zielstrukturen werden 
jedoch meistens auch auf normalen hämatopoietischen Stammzellen und nicht- 
hämatopoietischen Zellen exprimiert, was für klinische Anwendungen problematisch 
ist. Vor kurzem wurde entdeckt, dass AML-Stammzellen das CD96-Antigen 
(TACTILE)  exprimieren. Wichtig dabei ist, dass CD96 nur äußerst gering auf 
normalen hämatopoetischen Zellen nachzuweisen ist. CD96 wird auf den 
leukämischen Blasten bei rund 30% aller untersuchten AML Patienten und bei ver-
schiedenen Subtypen der AML membranständig exprimiert. Dadurch könnte CD96 
als Zielstruktur für CD96-gerichtete Immuntherapie geeignet sein. Ein CD96 
Antikörper TH-111 wurde von unserer Arbeitsgruppe generiert. Um für eine 
Anwendung im Menschen einen grossen Teil der potentiell immunogenen 
Maussequenzen des TH-111 Antikörpers zu entfernen, wurden die V-Regionen des 
murinen Antikörpers unter Verwendung von Phage-Display Technologie isoliert. 
CD96-scFv behielt die Bindungsspezifität des parentalen Antikörpers. Das isolierte 
scFv-Fragment wurde zur Klonierung von chimären CD96 Mini-Antikörpern (Fusion 
aus scFv und humanem IgG1 Fc-Teil) benutzt. Für den ADCC-Assay wurden die 
CD96-positiven-Zellen als Zielzellen und mononukleären Zellen (MNC) als 
Effektorzellen verwendet. Der CD96 Mini-Antikörper bewirkte nur eine geringe  
Effektorzell-vermittelte Lyse. Um höchaffine Antikörpervarianten zu generieren wurde 
mittels Error-prone-PCR zufällige Punktmutationen in das CD96-scFv cDNA-
Fragment eingebracht und Antikörpergenbibliotheken mit hoher Variabilität generiert. 
Durch stringente Selektionsmethoden wurden Antikörperklone mit verbesserten 
Bindungseigenschaften zu CD96 isoliert. Der mutierte CD96-scFv zeigte eine ca. 4-5 
fache höhere Affinität für CD96, verglichen mit dem Wildtyp-scFv. Die cDNA des 
 XX 
mutierten scFv wurde mit einem Wildtyp sowie einem für eine bessere Fc-Rezeptor 
Bindung optimierten humanen IgG1-Fc-Teil fusioniert. Der gereinigte mutierte CD96-
Mini-Antikörper wurde in ADCC Experimenten mit Wildtyp CD96-Mini-Antikörper ver-
glichen. In funktionellen Analysen (ADCC) war das Affinität-optimierte scFv Molekül 
(Mutant) mit mutieretem humanen IgG1-Fc-Teil dem Wildtyp scFv mit Wildtyp IgG1-
Fc-Teil deutlich überlegen. Aus den Versuchen kann geschlossen werden, dass eine 
Erhöhung der Affinität zum CD96 und zum Fc Rezeptor eine Steigerung der 
zytotoxischen Aktivität hervorruft. CD96-Mini-Antikörper könnten zur Eliminierung 
von Tumorzellen in vivo von Interese sein. Es ist geplant, CD96-Mini-Antikörper Ex 
vivo zum Purging von Stammzellpräparaten für Autologe Stammzellen weiter zu 
evaluieren.
 1 
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1. INTRODUCTION 
1.1 Acute myeloid leukemia (AML) 
Acute myeloid leukemia (AML) is a malignant disease of hematopoietic cells 
characterized by immature cells called blasts (Fig 1.1). AML is the most common 
acute leukemia among adults and its incidence increases with age (Sievers et al., 
2001). 80% of acute leukemia cases in adults and 15-20% in children are AML. The 
average age of a person with AML is 64 years. About 3600 new cases of AML occur 
in Germany each year, mostly in older adults. Regardless of progress in the therapy 
of AML, there is no long-term cure for about 70% of AML patients.  
 
Fig 1.1 AML blasts formation. Acute myeloid leukemia or AML is a cancer of the myeloid line of 
blood cells. In AML, the bone marrow makes many unformed cells called blasts. 
1.1.1 AML classification 
AML can be classified into various types. The AML classification is important since 
not all types of AML are treated in the same way. There are two major classifications 
for AML: The French-American-British (FAB) which is the first widely accepted 
classification and the World-Health-Organization (WHO) classification. The FAB 
classification of AML was established in 1976 and classified AML into eight major 
types. This classification is based on the degree of maturation, development phase 
and lineage differentiation of myeloblasts (Bennett et al., 1976; Bennett et al., 1985). 
The WHO classification of AML was established in 1999 and revised in 2009 
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(Vardiman et al., 2009). It classified AML according to morphological, immunological, 
cytogenetic, genetic, and clinical features.  
1.1.2 Hematopoietic stem cells (HSCs) and leukemia 
All blood cells arise from hematopoietic stem cells (HSCs). HSCs are hematopoietic 
cells with self-renewal potential (Ema and Nakauchi, 2003). HSCs generate a various 
number of hematopoietic cells by giving rise to multipotent progenitors (MPPs) and 
progenitors with limited dividing capacity. These progenitor cells are divided to 
lymphoid and myeloid progenitors, which give rise to various differentiated blood 
cells (Fig 1.2A) (Tan et al., 2006). Regulation of HSCs development is a critical 
element in the control of normal hematopoiesis (Ho and Punzel, 2003; Reya, 2003). 
The stem cell developmental schedule is strongly regulated by intrinsic factors and 
external stimuli such as soluble cytokines and contact with stroma (Zon, 2001). 
Dysregulation of stem cell developmental schedule causes abnormal expression of 
oncogenes, resulting in cancer cells proliferation (Godwin and Smith, 2003). 
Understanding the regulation factors which regulate this developmental program, and 
lead to the proliferative diseases such as leukemia, is one of the major challenges in 
biology (Frederick R. Appelbaum, 2001 ).  
 
Fig 1.2 Hematopoiesis and leukemia. Modified from (Tan et al., 2006). A) Normal hematopoietic 
stem cells (HSCs) and progenitor cells. HSCs can give rise to multipotent (MPPs) and oligopotent 
progenitor cells. These progenitor cells generate differentiated blood cells. B) Leukemic stem cells 
A B 
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(LSCs) and progenitor. LSCs arise from immature hematopoietic progenitors or from normal HSCs. 
LSCs give rise to clonogenic leukemic progenitors that differentiate into differentiated leukemic blasts. 
1.1.3 Cancer stem cells (CSCs) hypothesis  
According to the cancer stem cell hypothesis, these cells are a small subset of 
cancer cells, which are able to self-renew and recreate the cancer stem cell pool 
(Hope et al., 2004). The cancer stem cells are also able to differentiate into the 
heterogeneous nontumorigenic cancer cell types, responsible for the maintenance of 
the bulk of tumor (Clarke et al., 2006). Cancer stem cells are relatively resistant to 
conventional therapies which target rapidly dividing cells and their persistence 
explains the relapse of cancer diseases (Clarke et al., 2006). Therefore, recognition 
and elimination of the cancer stem cell population is crucial for cure of the cancer 
patients (Fig 1.3).  
 
Fig 1.3 Combination of cancer stem cells-directed therapy and conventional therapy. 
Conventional therapies generally target the bulk of tumors, resulting in the shrinking the tumors. 
These therapies are usually unsuccessful in targeting and eliminating the cancer stem cells. 
Therefore, the therapy can fail and the disease can relapse. According to cancer stem cell hypothesis, 
novel therapeutics which target and kill CSCs, together with conventional therapy, may help to cure 
the cancer patients. 
1.1.4 AML stem cells concept 
Acute myeloid leukemia with a hierarchy arrangement is an example of the cancer 
stem cells hypothesis. The leukemia stem cells (LSCs) are a subpopulation of AML 
CSCs-directed therapy + conventional therapy 
conventional therapy CSC 
Tumor 
relapse 
Tumor 
regression 
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cells which have long-term repopulating potential and ability to maintain and increase 
the AML phenotype. The LSCs are able to give rise to clonogenic leukemic 
progenitors. These progenitor cells differentiate into their differentiated progeny and 
leukemic blasts (Tan et al., 2006) (Fig 1.2B). The existence of leukemic stem cells 
has been long challenged (Huntly and Gilliland, 2005). The first supportive data was 
reported in 1988 using high-speed multiparameter flow cytometry (Spangrude et al., 
1988). It was demonstrated that human AML stem cells are found in the CD34+ 
CD38- cell population, similar to normal human primitive hematopoietic progenitors 
(Spangrude et al., 1988). Therefore AML stem cells may derive from normal 
hematopoietic stem cells or immature hematopoietic progenitors. In AML, some 
cytogenetic anomalies such as translocation t(8;21) occur in normal HSCs (Tan et 
al., 2006). CD34+ CD38- AML stem cells are able to regenerate human AML cell 
population in irradiated transplanted nonobese diabetic/severe combined 
immunodeficient mice, (NOD/SCID), but more committed progenitors which possess 
CD34+ CD38+ cell surface phenotype, do not have such potential (Lapidot et al., 
1994; Bonnet and Dick, 1997). In vitro studies demonstrated that AML stem cells are 
more resistant to chemotherapy than the CD34+ CD38+ progenitor cells (Costello et 
al., 1999). Remaining malignant CD34+ CD38- cells after chemotherapy, (minimal 
residual disease or MRD), cause the relapse of the disease (Feller et al., 2004). 
Recognition of differences between LSCs and normal hematopoietic stem cells and 
elimination of LSCs, could result in an effective therapy for AML patients. 
1.1.5 AML stem cell marker 
For an optimal AML stem cell-targeted therapy, it is necessary to recognize an 
antigen that is especially expressed on these cells. Different potential AML stem cells 
antigens such as CD123, CD33, CD44, and CD47 are described. But all of these 
antigens have some disadvantages such as expression on normal stem cells or 
nonhematopoietic tissues. CD123, the alpha subunit of the interleukin-3 receptor, (IL-
3Ra), is expressed on a variety of hematopoietic malignancies as well as LSCs 
(Jordan et al., 2000; Munoz et al., 2001). High expression of CD123 on CD34+ CD38- 
non-AML-regenerating bone marrow cells, (RBM), has also been reported (van 
Rhenen et al., 2007). In addition, CD123 antigen is expressed on normal HSCs. 
Therefore, CD123 is not an optimal target for AML stem cell-directed therapy. 
Gemtuzumab ozogamicin ,(GO), which is approved by FDA, is one of the 
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immunological approaches for targeting LCSs and treatment the AML patients 
(Sievers et al., 1999). GO is an antibody directed against CD33 which is conjugated 
to a cytotoxic agent. If GO is applied alone, many patients show the relapses 
(Sievers, 2001), since the majority of leukemic stem cells do not express CD33 
(Taussig et al., 2005). In addition, CD33 is highly expressed on normal CD34+ CD38- 
stem cells. Therefore the anti-CD33 can eliminate normal HSCs as well as LSCs 
(Taussig et al., 2005; van Rhenen et al., 2007) and can induce cytopenia (Sievers, 
2001; Kell et al., 2003). CD44 is another antigen on CD34 + CD38- leukemic stem 
cells. CD44 antibody ,(H90), can reduce the engraftment in NOD/SCID mice (Jin et 
al., 2006). But this antigen is also weakly expressed on normal CD34+ CD38-, more 
differentiated hematopoietic cells (Jin et al., 2006), and many different tissues (Ponta 
et al., 2003). CD47 is also highly expressed on AML-LSCs, as well as on normal 
tissues and bone marrow HSCs (Majeti et al., 2009). Expression of CD96 
,(TACTILE), was recently found on AML-LSCs, while only a very low expression level 
was found on normal HSCs (Hosen et al., 2007). 
1.1.6 CD96 (Tactile) 
CD96 also known as Tactile is a member of immunoglobulin gene super family. 
CD96 was previously introduced as a novel cell surface marker on NK cells and an 
antigen for T cell activation increased late expression ,(Tactile), (Wang et al., 1992; 
Gramatzki et al., 1998). This antigen has been recently reported as a target antigen 
on AML-LSCs (Hosen et al., 2007). 
1.1.6.1 Structure of CD96 
CD96 or tactile is a glycoprotein with a molecular weight of 160 kDa under reducing 
condition (Wang et al., 1992). This molecule is composed of a single pass 
transmembrane domain, a short cytoplasmic domain with 45 residues, and a long 
extracellular region with three immunoglobulin domains (Fig 1.4), (Wang et al., 
1992). The C-terminal of the extracellular domain is extensively glycosylated and is 
rich in serines, threonines, and pralines but has no cysteines. 2 Ig domains have two 
cysteines, and the most N-terminal Ig domain has five cysteines. These three extra 
cysteines are involved in the Ig disulfide bond (Wang et al., 1992). 
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Fig 1.4 Schematic structure of the CD96 antigen (Tactile). Modified from (Wang et al., 1992). 
Three immunoglobulin domains are displayed as loops. C: cysteine, attached black circles: N-
glycosylation sites, attached open circles: serines and threonines in the putative 0-glycosylated 
region, gray bar: plasma membrane. 
1.1.6.2 Expression of CD96 
CD96 is strongly upregulated in activated T and NK cells but has low expression in 
peripheral T and NK cells (Wang et al., 1992; Gramatzki et al., 1998; Hosen et al., 
2007). CD96 is expressed in a variety of T cell leukemia lines such as PEER, HSB, 
and HUT-78 (Gramatzki et al., 1998; Burger et al., 1999). Non-T cell lines, including 
fibroblasts and hepatoma cells which express T cell activation antigens, such as 
VLA-1, VLA-2, and CD26 do not express the CD96 antigen (Wang et al., 1992). 
CD96 was also detected in ~30% of human AML samples (Gramatzki et al., 1998). 
Tactile shows no expression on peripheral B cells, granulocytes, monocytes, and 
RBCs (Wang et al., 1992; Gramatzki et al., 1998). CD96 is expressed in 
nonhematopoietic tissue such as the mucosal epithelium of the small and large 
intestines, the convoluted tubular epithelium of the kidney and the vascular 
endothelium (Gramatzki et al., 1998).  
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1.1.6.3 CD96 monoclonal antibodies 
There are two known CD96 monoclonal antibodies, G8.5 and TH-111. The CD96 
monoclonal antibody G8.5 was generated by the immunization of mice with an IL-2-
dependent, alloantigen-specific human CTL line (Cytotoxic T Lymphocytes) (Wang et 
al., 1992). The CD96 monoclonal antibody TH-111 was generated by immunizing 
mice with a T-ALL cell line, HSB-2 cells  (Gramatzki et al., 1998). 
1.1.6.4 CD96 as a stem cell target antigen 
CD96 has been recently reported as a specific antigen on AML-LSCs (Hosen et al., 
2007). CD96 is expressed on functional AML-LSC. Transplantation of CD34+ CD38- 
CD96+ AML cells into irradiated newborn Rag2 -/- γc 
-/- mice resulted in an 
engraftment,  whereas CD34+ CD38- CD96- AML cells did not (Hosen et al., 2007). 
CD96 shows no expression on the majority of cells in the normal adult BM HSCs-
enriched population (Hosen et al., 2007). 
1.1.6.5 CD96 as a ligand for CD155 (PVR) in NK cells 
CD96 expressed on NK cells has been described as a ligand for CD155 or PVR 
,(Polio Virus Receptor), (Fuchs et al., 2004). NK cells distinguish PVR also through 
the DNAM-1 receptor (Bottino et al., 2003). CD96 binding to CD155 mediates the 
adhesion of NK cells to the target cells (Fuchs et al., 2004). Human CD96 can be 
expressed in two splice variants: variant 1 (L-like) or variant 2 (V-like) but the 
interaction with its ligand, CD155, is mediated through the outermost variant 2 and 
can be altered by this domain (Meyer et al., 2009). CD155 is a member of nectin and 
nectin-like family and is highly expressed on some tumors (Masson et al., 2001). 
Therefore cell-cell interaction between CD96-positive NK cells and tumor cells 
stimulates the cytotoxicity of these activated NK cells and promotes NK cell-mediated 
killing activities (Fuchs et al., 2004). This NK cells killing activity in mice is mediated 
through binding of CD96 to nectin-1 on target cells (Seth et al., 2007). Lacking of 
nectin-1 in mice mediates microphthalmia (Inagaki et al., 2005) and mutation in 
nectin-1 in humans mediates cleft lip/palate ectodermal dysplasia syndrome 
(CLPED) (Suzuki et al., 2000). A mutation in human CD96, or disruption of the 
genetic locus of CD96, can induce a form of C syndrome (Opitz-Trigonocephaly) 
(Kaname et al., 2007) since the adhesion activity between CD96 and its ligand, PVR,  
plays an important role in development processes. CD96 on AML-LSCs may also 
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show an interaction activity with its ligand on other cells in the bone marrow, possibly 
niche cells of AML-LSCs. In this case the binding activity of CD96 and its ligand can 
not mediate a killer function, but may take part in leukemia properties and may play a 
functional role in LSCs biology (Hosen et al., 2007). 
1.2 Antibodies (Immunoglobulins) 
Antibodies are glycoprotein molecules which are generated by B-lymphocytes and 
plasma cells in response to an antigen. Due to migration with globular proteins in an 
electrical field, the antibody is also called immunoglobulin. 
1.2.1 Human immunoglobulin structure   
Antibodies are Y-shaped macromolecules consist of two light chains with a low 
molecular weight (23 kDa) and two heavy chains with a higher molecular weight (50-
70 kDa) in a monomeric format (Fig 1.5). The N-terminal domains at the tip of the "Y" 
arms on both the heavy and light chains are variable in amino acid sequence and are 
known as variable domains. The other domains are called the constant region. The 
variable region contains the antigen binding site and the constant region determines 
the isotype and the functional properties of the antibody. Each heavy chain has one 
variable domain (VH) and three or four constant domains, depending on the isotype 
of antibody (CH1, CH2, CH3, and CH4). Each light chain has one variable domain 
(VL) and one constant domain (CL). The region between the CH1 and CH2 domains 
is called the hinge region because of the flexibility in the molecule at this point. There 
are different numbers of disulfide bonds in different immunoglobulin molecules. The 
heavy and light chains and the two heavy chains are bonded together by disulfide 
bonds (S-S). There are two types of light chains, kappa (κ) and lambda (λ), and five 
types of heavy chain, alpha (α), delta (δ), epsilon (ε), gamma (γ), and Mu (µ),  
according to the constant region. Corresponding to the types of heavy chains, 5 
immunoglobulin’s isotypes are known: immunoglobulin G (IgG), immunoglobulin A 
(IgA), immunoglobulin M (IgM), immunoglobulin E (IgE), and immunoglobulin D (IgD) 
(Table 1.1). Human IgG has four subclasses according to number of disulfide bonds 
and length of the hinge region: IgG1 (γ1 heavy chains), IgG2 (γ2 heavy chains), IgG3 
(γ3 heavy chains), and IgG4 (γ4 heavy chains). IgA is also divided in two subclasses: 
IgA1 (α1 heavy chains) and IgA2 (α2 heavy chains) (Table 1.1). There are three 
regions with a high ratio of different amino acids in variable region of heavy and light 
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chains of immunoglobulins which determine their specificity. These are called 
hypervariable regions (HVR) or complementarity determining regions (CDR): CDR1, 
CDR2, and CDR3. The remaining regions in the variable region are named the 
framework regions. There are four framework regions: FR1, FR2, FR3, and FR4. 
 
Fig 1.5 Schematic drawing of a simple immunoglobulin molecule (IgG).  VL: variable region of 
light chain,  VH = variable region of heavy chain (red), VL + VH = variable region,  CL + CH1 + 
CH2 + CH3 = constant regions, CH2 + CH3 = Fc; VL + CL = light chain, VH + CH1 + CH2 + CH3 = 
heavy chain, VH + CH1 + L chain = Fab, S-S = disulfide bond, and   CDRs: complementarity 
determining regions. 
Table 1.1 Overview of human immunoglobulin classes and subclasses. 
Ig isotype Light chain Subtype Heavy chain Basic structure 
IgA 
κ or λ 
κ or λ 
IgA1 
IgA2 
α1 
α2 
Dimer and 
Monomer 
IgE κ or λ None ε Monomer 
IgD κ or λ None δ Monomer 
IgM κ or λ None µ Pentamer 
IgG 
κ or λ 
κ or λ 
κ or λ 
κ or λ 
IgG1 
IgG2 
IgG3 
IgG4 
γ1 
γ2 
γ3 
γ4 
Monomer 
Digestion of the immunoglobulin with papain, (a cysteine protease enzyme), breaks 
the molecule into two equal fragments containing the whole light chain and the VH 
and CH1 domains of the heavy chain (Fig 1.6). These fragments contain the antigen 
binding sites of antibody and are called the Fab fragments (fragment antigen-
binding). The rest of the two heavy chains after digestion with papain containing two 
Antigen binding sites 
 
Fab 
Fc 
Hinge 
-s-s- -s-s- 
-s-s- 
-s-s- 
CH2 
CH3 
CL 
VL 
VH 
CH1 
CDR 
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or three constant domains are called the Fc region, (fragment crystallizable region), 
(Fig 1.6). The Fc region can modulate the immune cell activity through binding to the 
Fc receptors of the immune cells or immune molecules and complement proteins. 
Digestion of the immunoglobulin with pepsin cleaves the heavy chain after the 
disulfide bonds and forms a fragment containing both antigen binding sites (Fig 1.7). 
This fragment is called F(ab')2. The F(ab')2 can bind to antigen but it does not 
mediate the effector functions of antibodies. 
 
 
 
Fig 1.6 Schematic drawing of digestion an immunoglobulin molecule with papain. 
 
 
 
Fig 1.7 Schematic drawing of digestion an immunoglobulin molecule with pepsin. 
1.2.2 Therapeutic antibodies 
1.2.2.1 Murine monoclonal antibodies 
The technique to generate monoclonal antibodies was developed by Köhler and 
Milstein (Kohler and Milstein, 1975) by developing murine hybridoma cells lines, and 
producing specific monoclonal antibodies targeting specific antigens. In 1986 the 
Papain 
Pepsin 
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CD3 antibody muromonab ,(Orthoclone OKT3), was approved as a first monoclonal 
antibody in US (Reichert et al., 2005). Muromonab is an antibody of mouse origin 
which was used as an immunosuppressant to prevent transplant rejection (Goldstein 
et al., 1986). Muromonab could also decrease CD3+ tumor cells in T cell acute 
lymphoblastic leukemia (Gramatzki et al., 1995). But the dissimilarity of human and 
murine immune systems led to rapid sensitization with the induction of human anti 
mouse antibodies (HAMA), which decrease efficacy of the mouse antibody in human 
immune system. Furthermore, mouse antibodies are not efficient in recruiting the 
human immune system and human effector functions (Shin, 1991). Therefore, the 
mouse antibodies were replaced with recombinant antibodies by the process of 
genetic engineering through chimerization (Morrison et al., 1984) and humanization 
(Riechmann et al., 1988), to overcome the problem of HAMA and other 
disadvantages of mouse antibodies. The recombinant antibodies can also be radio-
labeled, or conjugated to toxins, for targeting the special tumor cells (Carter, 2006). 
Several recombinant antibodies are approved in Europe as therapeutics directed 
against cancer (Deonarain, 2008), and many other antibodies are in various stages 
of clinical studies (Carter, 2006).  
1.2.2.2 Chimeric antibodies 
A chimeric antibody consists of the variable region of a mouse antibody combined 
with constant regions of human immunoglobulin (Fig 1.8). A chimeric antibody 
consists of approximately 65% human antibody and is named with the suffix “ximab”. 
Abciximab was the first FDA-approved therapeutic chimeric antibody, which has 
been directed against the GPIIb/IIIa receptor on platelets and prevents clotting 
(Simoons et al., 1994). Abciximab was a Fab fragment. In 1997 rituximab was 
approved as a chimeric antibody, whole monoclonal IgG molecule, for the treatment 
of non-Hodgkin’s lymphoma ,directed against the CD20 antigen (Anderson et al., 
1997). Rituximab is one of the most clinically used antibodies (Peipp and Valerius, 
2002).  
1.2.2.3 Humanized antibodies 
Humanized antibodies have more similarity to human antibodies compared to 
chimeric antibodies. A humanized antibody is generated by introducing the six 
hypervariable genes (CDRs) of a mouse antibody into a human framework sequence 
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and merging with human constant regions (Fig 1.8). This antibody has 90% coding 
sequences from a human antibody and is named with the suffix “zumab”. Daclizumab 
(Zenapax®) is the first humanized antibody which was approved in 1997. This 
antibody is directed against the CD25 antigen for the prevention of acute organ 
rejection (Ekberg et al., 1999). In 1998 trastuzumab (Herceptin®), a humanized 
antibody specific for HER2/neu, was approved as a first humanized anticancer 
antibody (Roche and Ingle, 1999). 
1.2.2.4 Human monoclonal antibodies 
Human monoclonal antibodies are developed from display technologies such as 
yeast, ribosome or phage display (Hoogenboom, 2005) or developed from transgenic 
mice which express human immunoglobulin genes after vaccination with desired 
antigen (Lonberg, 2008). Human antibodies are named with the suffix “umab”. 
Adalimumab (Humira®) was the first fully human monoclonal antibody derived from 
phage display and was approved in 2002 for the treatment of rheumatoid arthritis 
targeting TNF‐α (Scheinfeld, 2003). Panitumumab (Vectibix®) was the first fully 
human monoclonal antibody derived from transgenic mice, and was approved in 
2006 for the treatment of colon cancer, targeting the epidermal growth factor receptor 
(EGFR) (Chu, 2006).  
 
Fig 1.8 Schematic view of mouse, chimeric, humanized, and human antibodies. Modified from 
(Joost Bakker, Genmab). Mouse parts are shown in yellow and human parts in green. 
1.2.2.5 Single-chain variable fragment (scFv) 
Recombinant Fab fragments and single chain variable fragments, are the most 
commonly used formats of recombinant antibody constructs (Peipp et al., 2004). 
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ScFv is a fusion of the variable domains of the light and the heavy chains of 
immunoglobulins, bonded together with a short peptide linker (Fig 1.9). ScFv has a 
molecular mass of ~ 25 kDa. The linker includes 10 to 25 amino acids which are 
mainly glycine for flexibility and serine for solubility of the molecule (Le Gall et al., 
2004). ScFv molecules can be generated using antibody engineering and phage 
display technology (Krebber et al., 1997; Hoogenboom and Chames, 2000; 
Hoogenboom, 2005). Single chain variable fragment antibodies are generally applied 
as research and therapeutic reagents (Blažek and Celer, 2003) and are very 
valuable for the elimination of tumor cells, targeted delivery of drugs, toxins or 
radionuclides. ScFvs have quicker blood clearance compared to fab, f(ab)2 and 
complete IgG molecules (Hudson, 1999). Due to their small size, scFvs show better 
tissue penetration in comparison to complete immunoglobulin molecules (Milenic et 
al., 1991; Yokota et al., 1992; Adams et al., 1993). Regardless of the absent constant 
regions and possessing linker, the scFv molecule retains the binding specificity of the 
parental immunoglobulin for the target antigens, since scFv includes the 
complementarity determining regions (CDRs). ScFvs can be expressed in E. coli 
cells.  
 
Fig 1.9 Schematic drawing of scFv formation. ScFv is a fusion of  VL and  VH from IgG1 
molecule, connected together with a linker (black line). 
1.3 The phage display recombinant antibody system 
Phage display technology was established in 1985 by George Smith (Smith, 1985). 
This is a powerful tool to generate a large number of functional peptides and proteins 
such as single chain variable fragments (Azzazy and Highsmith, 2002). A foreign 
VH 
VL 
scFv 
-s-s- 
-s-s- 
-s-s- 
-s-s- 
CH2 
CH3 
CL 
VL 
VH 
CH1 
Mouse IgG1 
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DNA fragment can be inserted into a suitable phage coat protein gene using genetic 
engineering tools. This recombinant gene can be functionally displayed as a fusion 
protein on the surface of a bacteriophage and the high affinity and specifity antibody 
fragments can be selected.  
1.3.1 Filamentous bacteriophage 
The filamentous phages are mainly used in display technology. They are identified as 
Ff phages, due to infection of E. coli cells through the bacterial F conjugative pilus. 
There are different strains of filamentous bacteriophages including M13, f1, Fd , and 
ft (Yacoby and Benhar, 2008). The genomes of these phages have 98% homology 
and therefore their gene products/proteins are almost the same (Beck and Zink, 
1981; Hill and Petersen, 1982; Van de Winkel and Capel, 1993). The most generally 
used filamentous bacteriophage for displaying scFvs fragments is M13 phage 
(Manoutcharian et al., 2001). Filamentous bacteriophages M13 utilized in phage 
display technology are circular and single-stranded DNA viruses (ssDNA) 
(Manoutcharian et al., 2001). These viruses infect a variety of gram-negative bacteria 
via their F pili. The DNA of bacteriophage includes 6407 nucleotides, which are 
wrapped in a long capsid protein cylinder with a diameter of 7 nm and 930 nm in 
length (Crissman and Smith, 1984). The capsid includes five coat proteins named 
pVIII, pIII, pVI, pVII, and pIX. The major coat protein, PVIII, with 50 aa, surrounded 
the phage DNA along its major axis with its 2700 copies. 3 to 5 copies of the proteins 
PIII and pVI are located in one end of phage, and 3 to 5 copies of the proteins pIX 
and pVII are located in another end of phage (Webster, 2001). PIII is a 406 aa 
protein, and mostly used for peptide expression. PIII has two functional domains: 1) 
N-terminal domain, which is exposed to the surroundings and binds to the F pilli of E. 
coli cells, but it is not necessary for phage particle assembly. 2) C-terminal domain, 
which is located inside of the phage particle, close to the DNA, and is an essential 
part of the capsid structure. The recombinant fragments are usually expressed as pIII 
or pVIII fusion proteins and are displayed at the tip of the bacteriophage 
(Hoogenboom et al., 1991; Willats, 2002).  
1.3.2 Construction of a phage display library 
Antibody fragments such as scFvs, diabodies, and Fab fragments can be displayed 
on the surface of a phage (Rader and Barbas, 1997). Gene sequences of 
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recombinant protein can be inserted into the gene of the coat proteins, pIII or pVIII. 
Phage DNA is replicated in E. coli as a double stranded plasmid, and super infection 
with the helper phages causes the single-stranded phagemid DNA, which is 
packaged in phage particles. The bacteriophage replicates its DNA together with 
foreign DNA (Smith and Petrenko, 1997). The helper phages provide all the proteins 
which are required for phage assembly, including copies of the wild type coat 
proteins (Bass et al., 1990) (Fig 1.10). Therefore the yielding phage contains both the 
wild type coat protein from the helper phages and also the fusion coat proteins from 
the phagemid which can be displayed as N-terminal fusions to pIII, pVIII (Bass et al., 
1990) or pIX (Gao et al., 1999). C-terminal display can be realized with pVI, pIII, and 
pVIII (Fuh and Sidhu, 2000). A possible difficulty of phage system is the reduction of 
average number of displayed fusion molecules because of competition with wild type 
coat proteins (Winter et al., 1994). 
 
Fig 1.10 Schematic view of phage display. ScFv gene can be fused to a gene of bacteriophage. 
ScFv protein can be expressed as pIII, pVIII or pIX fusion protein and displayed at the tip of 
bacteriophage. 
1.3.3 Screening  
During the cloning of the scFv genes,  heavy and light chains are combined randomly 
and through phage display, each bacteriophage can display a unique antibody with a 
specific antigen binding site on its surface (Rader and Barbas, 1997; Pini and Bracci, 
2000). The genetic information encoding the displayed molecule is contained within 
the phage coat, thus providing a direct physical link between genotype and 
phenotype (Rader and Barbas, 1997). This linkage allows the selection and 
phage coat 
scFv gene 
phage gene III 
protein gIII 
VH 
VL 
scFv 
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amplification of a specific clone from a pool with millions phages. During the 
screening of a phage library, the displayed proteins bind to the specific antigen. The 
bound phages can be identified with a M13-HRP-conjugated antibody that 
recognizes the phage coat proteins.  
1.4 Antibody effector functions 
The effector mechanisms of antibodies can be divided into direct mechanisms and 
indirect mechanisms (Houghton and Scheinberg, 2000). Direct mechanisms are 
mediated by the variable regions and indirect mechanisms are triggered by constant 
domains of antibodies (Peipp et al., 2008a). Antibodies can distinguish exogenous 
particles such as pathogens and allergens, or endogenous antigens such as tumor 
cells antigens through two Fab fragments. The Fc domain of antibody is able to 
induce effector functions, such as the activation of complement system (Casadevall 
et al., 2004). For most antibodies, a combination of various effector mechanisms is 
supposed to work together in vivo (Glennie and Van De Winkel, 2003).  
1.4.1 Direct mechanisms 
Antibody direct mechanisms include cross-linking of antigen, activation of death 
receptors, induction of apoptosis or programmed cell death, proliferation inhibition, 
avoidance of receptor-dimerization, and neutralization of soluble factors (Ludwig et 
al., 2003; Dübel, 2007). Some therapeutic antibodies can block tumor cells growth by 
targeting growth factor receptors, such as the epidermal growth factor receptor 
family, to block the ligand binding, or dimerization of the growth factor receptors 
which is required for transduction of activating signaling pathways (Sunada et al., 
1986; Li et al., 2005). Some antibodies can  target the vascular endothelial growth 
factor to block tumor associated angiogenesis, as well as adhesion molecules to 
block interaction with stroma cells, and slow down the tumor growth and metastasis 
(Lafrenie et al., 2007). Some monoclonal antibodies are able to affect cell cycle and 
induce apoptosis. Apoptosis is a regulated process of programmed cell death in 
response to specific signals or DNA damage (Lowe and Lin, 2000; Ghobrial et al., 
2005). This modulation of regulatory and survival signaling pathways are not enough 
for most therapeutic antibodies to eradicate tumor cells. Therefore the recruitment of 
secondary immune effector mechanisms is very important for effective antibody 
therapy (Nimmerjahn and Ravetch, 2007).  
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1.4.2 Indirect mechanisms 
Complement-dependent tumor cell lysis (CDC) and effector cell-mediated tumor 
killing (ADCC) are two important indirect mechanisms, performed through 
interactions between the constant regions of the antibodies and effector molecules. 
1.4.2.1 Antibody-Dependent Cell Mediated Cytotoxicity (ADCC) 
ADCC is an important effector mechanism for most therapeutic anticancer antibodies 
(Houghton and Scheinberg, 2000). Through ADCC, the antibodies bind to the target 
cell antigens and recruit the innate immune effector cells, such as natural killer cells 
(Fig 1.11). The immune effector cells have specific receptors, (Fc receptors), for the 
constant region of the antibody and can mediate phagocytosis, or release the 
inflammatory mediators or cytotoxic granules, to eliminate the targeted tumor cells 
(Ravetch and Kinet, 1991). Natural killer cells are the most common effector cells 
which mediate ADCC. Subsequent to binding of NK cells to Fc region of antibody, 
they can destroy the target cells with release the granules which contain perforin and 
granzymin B, and/or activation of the FAS/FAS ligand apoptosis system in the target 
cell. Perforin molecules create holes or pores in the membrane of tumor cells, which 
disturb the osmotic barrier and eliminate the tumor cells by osmotic lysis. Mouse 
IgG2a, human IgG1, and IgG3 
subclasses mediate ADCC effectively (Clynes et al., 
2000).  
 
Fig 1.11 Antibody-Dependent Cell Mediated Cytotoxicity (ADCC). Through ADCC, the antibodies 
bind to the target cell antigens and recruit the innate immune effector cells such as natural killer cells 
(NK). The clinical efficacy of therapeutic antibodies in vivo can be enhanced by increasing affinity to 
activating Fc receptors and by reducing affinity to the inhibitory Fc receptor. 
Inhibitory FcR 
 
Tumor cell Effector cell 
Activating FcR 
 
Target antigen 
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1.4.2.2 Complement-dependent cell-mediated cytotoxicity (CDC) 
Complement-dependent cell-mediated cytotoxicity is an important effector 
mechanism for elimination of foreign agents and tumor cells. Through CDC, the 
antibodies eliminate the targeted cells by triggering the complement cascade on the 
cell surface. The complement system consists of classical, lectin, and alternative 
pathways. For the classical pathway, the immunoglobulins are necessary, but the 
lectin and alternative pathways are activated mainly by microbial elements. For 
activation of the classical pathway, the first complement component (C1q) binds to 
the Fc portion of the immunoglobulin. Following this binding, a proteolytic 
complement cascade is triggered, and a large amount of the main effector molecule 
of the complement system, (C3b), is generated. C3b molecules act as phagocytosis 
enhancer, and can bind to the C3 convertase to create a C5 convertase (Cartron et 
al., 2004). Activation of the complement system finally leads to formation of the 
membrane attack complex, (MAC), (C5b to C9). This has a function similar to 
perforin, and forms transmembrane holes or pores that disrupt the osmotic barrier of 
the membrane and lead the tumor cells to osmotic lysis (Cartron et al., 2004). C3b 
can also bind to complement receptors (CRs) on effector cells such as granulocytes, 
macrophages, and NK cells. This induces cell-mediated lysis or phagocytosis, 
depending on the effector cell complement dependent cellular cytotoxicity (CDCC). 
Human IgG3 and IgG1 mediate the most effective CDC. IgG2 mediates low CDC, 
and IgG4 mediates no CDC. 
1.4.3 Fc receptors (FcRs)  
The efficient interaction of the antibody Fc region with cellular Fc receptors, on innate 
immune effector cells, is a very important factor for antibody activity in vivo 
(Nimmerjahn and Ravetch, 2007). There are specific FcRs for the immunoglubuline 
classes: FcR for IgA is FcαR, for IgD is FcδR, for IgE is FcεR, for IgG is FcγR, and 
for IgM is FcµR. Human Fcγ receptors, (FγRs), for the Fc region of IgG, are main 
mediators of the adaptive immune response (Sondermann and Oosthuizen, 2002). 
Human IgG1 with its high ADCC effect is the most suitable therapeutic agent against 
cancer cells. There are four different classes of FcγRs for IgG molecules: FcγRI 
(CD64), FcγRII (CD32), and FcγRIII (CD16). These FcRs are different in affinity for 
IgG subtype, cell expression, and receptor structure (Van de Winkel and Capel, 
1993; Hulett and Hogarth, 1994). FcγRI has the highest affinity but FcγRII and 
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FcγRIII have a low affinity. FcγRs are expressed on different immune effector cells 
such as monocytes, NK cells, and macrophages (Van de Winkel and Capel, 1993). 
FcγRI (CD64) is expressed on monocytes and macrophages and can also be 
expressed on neutrophils (Repp et al., 1991). FcγRI has four isoforms: FcγRIa, 
FcγRIb1, FcγRIb2 and FcγRIc. FcγRII (CD32) is expressed on several immune cells. 
FcγRII can be in FcγRIIa1, FcγRIIa2, FcγRIIb1, FcγRIIb3, and FcγRIIc isoforms. 
FcγRIII (CD16) is expressed in two isoforms, FcγRIIIa which is expressed on NK and 
T cells and FcγRIIIb which is expressed on neutrophils.  
The basic structure of FcγR consists of an extracellular part, (EC), with two or three 
immunoglobulin-like domains, a hydrophobic transmembrane, region (TM), and an 
intracytoplasmic end, (IC), (Qiu et al., 1990). The extracellular domain of FcγRI has 
three immunoglobulin-like domains and can be activated by the monemer form of 
IgG molecule. FcγRII and FcγRIII have one extracellular domain less than FcγRI, 
and must bind multiple IgG molecules to activate an immune complex. The 
cytoplasmic domains of FcγRI, FcγRIIa/c, and FcγRIIIa have an immunoreceptor 
tyrosine based activation motif (ITAM), and are therefore activating receptors. But the 
FcγRIIb has the immunoreceptor tyrosine based inhibitory motif (ITIM), and is an 
inhibitory receptor (Warmerdam et al., 1990). Activation receptors are required, and 
inhibitory receptors should be blocked, for the efficacy of therapeutic antibodies 
(Clynes et al., 2000). 
Table 1.2 Fcγ receptors in human. Modified from (Griggs and Zinkewich-Peotti, 2009). DC = 
dendritic cell, ITAM = immunoreceptor tyrosine-based activation motif, ITIM = immunoreceptor 
tyrosine-based inhibitory motif, mΦ = macrophage, N = neutrophil, B = B cell, NK = natural killer cell.  
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1.5 Optimizing antibody ADCC activity 
ADCC is an important mechanism of therapeutic antibodies in cancer therapy. 
Therefore to enhance the clinical efficacy and the antitumor potency of antibodies, 
their ability to mediate cellular cytotoxic effector functions such as ADCC can be 
improved (Weiner and Carter, 2005). 
1.5.1 Optimizing antibody binding affinity to Fc receptors on immune effector 
cells  
Xenograft studies with some therapeutic antibodies such as rituximab and 
trastuzumab in FcγR knockout mice, demonstrated that the improvement of the 
clinical efficacy of these antibodies in vivo can be reached by increasing antibody 
binding affinity to activating Fc receptors, and by reducing binding affinity to the 
inhibitory Fc receptor (Clynes et al., 2000; Nimmerjahn and Ravetch, 2005) (Fig 
1.11). There are two main approaches to optimizing Fc receptor interaction: 
modulation the mutations in the cDNA of corresponding antibody (protein 
engineering) to altering the structure of the Fc region (Duncan et al., 1988; Sarmay et 
al., 1992; Lazar et al., 2006), and modifying the glycosylation profile of antibody 
(glyco-engineering) (Uma a et al., 1999; Shields et al., 2001; Okazaki et al., 2004; 
Peipp et al., 2008c).  
1.5.1.1 Mutations  
Human IgG1 is the most commonly used antibody isotype for tumor therapy 
(Ravetch and Bolland, 2001). The clinical efficacy of a human IgG1 antibody is 
dependent on the binding affinity of Fc portion of antibody to FcγR on effector cells 
(Cartron et al., 2002). Therefore an IgG1 antibody with optimized FcγR binding 
represents efficient cytotoxic effects against targeted tumor cells (Cartron et al., 
2004). Mutation and change of the amino acid in Fc regions of antibodies to 
optimizing Fc receptor binding can be performed either by alanin scanning 
mutagenesis (Shields et al., 2001), or by computer-based calculation methods 
(computer algorithms) (Lazar et al., 2006).  
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1.5.1.2 Deglycosylation  
Carbohydrate optimization can improve the cytotoxic effector functions of therapeutic 
antibodies. IgG molecules are heterogeneous, with the fucose attached to the Asn-
297 glycosylation site. Deletion of this fucose in the CH2 domain of antibody can 
increase cytotoxic activity of mouse and all human IgG antibody isotypes (Shinkawa 
et al., 2003; Niwa et al., 2005). It has also been reported that ADCC efficacy with 
isolated mononuclear effector cells, is enhanced for low-fucosylated antibodies in 
comparison with the high-fucosylated variant of the same antibody (Shields et al., 
2002; Okazaki et al., 2004; Schuster et al., 2005). Some other studies demonstrated 
that removal of the fucose at this glycosylation position in some antibodies, enhanced 
their binding affinity to FcγRIIIa, but binding to some other Fcγ receptors is 
independent from this modification (Uma a et al., 1999; Shields et al., 2002; Okazaki 
et al., 2004). Furthermore, the efficacy of glycol-engineered antibodies could 
significantly be change by effector cell type (Peipp et al., 2008c).  
1.5.1.3 Deletion of terminal sialic acid residues 
It has been reported that the lack of terminal sialic acid residues, in the antibody 
sugar side chain, can improve cytotoxic activity efficacy in humans and mice 
(Rademacher et al., 1994; Kaneko et al., 2006; Scallon et al., 2007). Also an 
elevated level of sialic acid can decrease antibody binding to both FcγRIIIa and cell 
surface antigen, (Scallon et al., 2007) and reduce ADCC activity. 
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Fig 1.12 Optimizing antibody and Fc receptors interaction. Modified from (Nimmerjahn and 
Ravetch, 2007). The efficient anti cancer ADCC activity of antibody can be achieved by optimizing the 
interaction of the antibody Fc-portion with activating FcRs and by blocking the inhibitory FcR. ITAM: 
the immunoreceptor tyrosine based activation motif, ITIM: the immunoreceptor tyrosine based 
inhibitory motif. 
1.5.2 Antigen density on target cells 
The antigen density on tumor cells is another factor that affects ADCC. It has been 
reported that target cells with a higher antigen expression level are more competent 
to be eradicated by an antibody through ADCC (Tang et al., 2007). The low antigen 
density can even reduce ADCC activity of high affinity IgG antibodies (Tang et al., 
2007). This is because more antibody molecules can bind the target cells which 
express a high level of corresponding antigen, and a stronger ADCC can be 
performed in comparison to the target cells which express fewer antigens.  
1.5.3 Antibody binding affinity to target antigen 
Human IgG affinity can affect the ability of antibodies to mediate ADCC (Tang et al., 
2007). It has been reported that IgG antibodies with higher binding affinities to target 
antigens, promote more ADCC by human NK cells in comparison to IgG antibodies 
with a lower affinity to target antigen (Tang et al., 2007). In the human immune 
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system, the efficient immune response against foreign antigens generally depends 
on the generation of high affinity antibodies. The antibodies, which are generated in 
the primary immune response, usually have moderate binding affinities, but these 
affinities are maturated and enhanced in later responses with a process of 
hypermutation (Kocks and Rajewsky, 1988). The hypermutation occurs in the 
antibody V-genes of B cells in germinal centers (Berek et al., 1991; Jacob et al., 
1991) (Fig 1.13). Antibodies may obtain several mutations, but the most 
enhancement in binding affinity is achieved by the mutation of a few residues within 
the antigen binding site (Berek and Milstein, 1987). This immune system 
characteristic introduced a potent means for the generation of antibodies with high 
binding affinities in vitro (Winter and Milstein, 1991). Recombinant antibodies can be 
generated on the surface of bacteriophages by the mimicking of primary immune 
response (Low et al., 1996). The secondary immune response, and antibody affinity 
maturation can also be mimicked in vitro by mutations of antibodies variable genes 
(Fujii, 2004). The phage antibody mutants can be screened by binding to its antigen, 
during several rounds of screening, with an increasingly stringent selection condition, 
to select mutants with enhanced binding affinities. 
 
 
 
 
Fig 1.13 Hypermutation of antibody genes in germinal centers. Modified from (Low et al., 1996). 
During maturation of B cells, before differentiation into plasma cells, the antibodies V-genes undergo 
somatic hypermutation to generate antibodies with high affinity for their target antigens. 
A previous study from Tang and his colleagues demonstrated that only very low 
concentration of a high affinity scFv-IgG antibody (H3B1 IgG) directed against 
HER2/neu antigen, is required to mediate ADCC in comparison to the antibody 
variant with lower affinity (G98A IgG) (Tang et al., 2007). It has also been reported 
that multivalent binding to the tumor antigen mediates ADCC more efficiently in 
comparison to monovalent binding (Shahied et al., 2004). Affinity Maturation by PCR-
     Germinal Center 
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Mutagenesis is an efficient approach to mimic the process of somatic maturation in 
the immune system to select the antibodies with a higher affinity to target antigens. 
PCR-Mutagenesis can be site-directed to introduce diversity at specific locations, 
usually CDRs, or can be randomly mutated in VL and VH regions. The mutated 
library has to be very large to express approximately the total immune repertoire and 
the screening of high affinity target antigen binders (Marks et al., 1991; Vaughan et 
al., 1996). The mutation frequency, low, medium, or high, can usually be controlled 
by varying the DNA amount (Table 1.3). Low amounts of DNA undergo more 
duplications than high amounts of DNA. 
Table 1.3 Mutation frequencies vs. initial target quantities. A low, medium or high mutation 
frequency can be produced by adjusting the initial target DNA amounts in the PCR reaction. 
Mutation 
 rate 
Mutation frequency 
(mutations/kb) 
Initial target amount 
(ng) 
Recommended fold 
amplification 
Low 0-4.5 500-1000 1.5-10 
Medium 4.5-9 100-500 10-100 
High 9-16 0.1-100 100-10,000 
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2. MATERIALS & METHODS 
2.1 Materials  
2.1.1 Mammalian cell lines 
Cell line Cell type Culture  Medium source 
CEM human T cell leukemia suspension 90% Dulbecco´s MEM + 10% 
FBS + 1% Pen/Strep  
DSMZ 
HSB-2 human T cell leukemia  suspension 90% RPMI 1640 + 10% FBS + 
1% Pen/Strep  
DSMZ 
KG1a human acute myeloid 
leukemia 
suspension 90% RPMI 1640 + 10% FBS + 
1% Pen/Strep  (R10+) 
DSMZ 
TH-111 CD96-hybridoma cells adherent 90% RPMI 1640 + 10% FBS + 
1% Pen/Strep  (R10+) 
(Gramatzki 
et al., 
1998) 
293T human embryonal kidney adherent 90% Dulbecco´s MEM + 10% 
FBS + 1% Pen/Strep  
DSMZ 
2.1.2 Cell culture media and additives 
Mammalian cell culture  Source  
CryoSure-DMSO  WAK-Chemie Medical  
DMEM, Dulbecco’s Modified Eagle medium  Invitrogen 
Fetal bovine serum (FBS)  Invitrogen 
GM-CSF CellGenix 
Hank’s medium  PAA 
Hygromycin B in PBS, 50mg/ml  Invitrogen 
Lipofectamine LTX  Invitrogen 
Opti-MEM + glutamine, reduced serum  Invitrogen 
Penicillin/streptomycin, 10,000 U/ml Penicillin, 10,000 µg/ml Streptomycin Invitrogen 
Percoll  Biochrom 
Phytohemagglutinin-M (PHAM) Roche 
RPMI1640 + GlutaMAX-I medium  Invitrogen 
Trypsin/EDTA (1x) Invitrogen 
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2.1.3 Escherichia coli strains and helper phage 
E.coli strains Genotypes Source 
BL21 (DE3) 
Electrocompetent 
B F- ompT hsdS(rB
- mB
-) dcm+ Tetr gal λ(DE3) endA Hte  Stratagene 
HB2151 
Electrocompetent 
 [∆(lac-pro) ara nalr thi/F' proAB LacIq lacZ∆M15] 
 
Dr. G. Winter, MRC 
Cambridge, UK 
Mach1 
Chemocompetent 
lacZ∆M15 hsdR lacX74 recA endA tonA Invitrogen 
TG1 
Electrocompetent 
supE thi-1 ∆(lac-proAB) ∆(mcrB-hsdSM)5 (rK
-mK
-) [F´ 
traD36 proAB lacI
q
Z∆M15] 
Stratagene 
XL1-Blue 
Electrocompetent 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ 
proAB lacI
q
Z∆M15 Tn10 (Tetr)] 
Stratagene 
 
Helper phage  Source 
M13KO7 New England Biolabs 
2.1.4 Cultures for bacterial cells 
Bacterial culture  Source  
Glucose  Carl Roth  
IPTG Carl Roth  
LB medium Carl Roth  
PEG 6000 Carl Roth  
SOB medium Carl Roth  
SOC medium SOB + 20% Glucose  
2xTY medium Carl Roth  
2xTY-Agar Carl Roth 
2.1.5 Antibiotics for bacterial culture 
Antibiotics  Stock solution Working solution 
Ampicillin 100 mg/ml 100 µg/ml 
Chloramphenicol 30 mg/ml 30 µg/ml 
Kanamycin 50 mg/ml 25 µg/ml 
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Stock solutions of antibiotics were stored at -20°C. All bacterial culture media were 
autoclaved. The appropriate antibiotic was added to medium after lowering the 
temperature to RT and before use. 
2.1.6 Primers  
LB/HB and LF/HF: (Krebber et al., 1997) 
Scfor and  Scback: (Krebber et al., 1997) 
ECD-For: 5’-GATCGCTAGCCACCATGGAGAAAAAATGGAAATACTGTGCTGTC-3’  
ECD-Rev: 5’-CACAGCGGCCGCCATCTTTGGGCTTATTGACCACAATACC-3’ 
Mut-Scfor: 5’-GATCGGCCCAGCCGGCCATGGCGGACTACAAAGAC-3’  
Mut-Scback: 5’-GATCGGCCCCCGAGGCCGCAGAGACAGTGACCAG-3’ 
2.1.7 Vectors 
pAK100 Kindly provided by Dr. Plückthun (Krebber et al., 1997) 
pAK400 Kindly provided by Dr. Plückthun (Krebber et al., 1997) 
pSec-IgG1-Fc  (Repp et al., 2010) 
pSec-IgG1-Fc-eng (Lazar et al., 2006; Repp et al., 2010) , 3 mutations in CH2 
(S239D/I332E/A330L) 
2.1.8 Enzymes 
Enzymes Source 
PeqGOLD PWO DNA Polymerase Peqlab 
PeqGOLD Taq DNA Polymerase  Peqlab 
Restriction enzymes New England Biolabs 
SuperScript™ II Reverse Transcriptase  Invitrogen 
T4 DNA ligase Roche 
2.1.9 DNA and protein markers 
Markers Source 
100 bp-DNA Ladder Carl Roth 
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Precision Plus Protein, Dual Color Standard Bio-Rad 
2.1.10 Antibodies and conjugates 
Antibodies and conjugates Source 
Anti CD96-PE eBioscience 
Anti-human IgG1-FITC Beckman-Coulter 
Anti-human IgG HRP-conjugated antibody  Sigma-Aldrich 
Anti-mouse IgG1-FITC Sigma- Aldrich 
Anti-mouse IgG HRP-conjugated antibody Sigma-Aldrich 
Anti-M13 HRP-conjugated antibody Amersham pharmacia  
Erbitux Merck 
Penta.His Alexa fluor conjugate Qiagen 
Penta-His Antibody Qiagen 
2.1.11 Buffers and reagents 
Buffer Source/Components 
Coomassie staining solution 20% (w/v) Roti-Blue 5x (Carl Roth) in destaining solution (20% 
Methanol + 60% H2O) 
DNA gel loading buffer Carl Roth  
DPBS Invitrogen 
PEG/NaCl  20% (w/v) PEG-6000, 2.5 M NaCl  
Periplasmic extraction buffer 100 mM Tris/HCl, 500 mM Sucrose, 1 Mm EDTA, (pH 8.0) 
PFA fixation buffer 1% Paraformaldehyd/PBS 
SDS loading buffer (5x) 30% Glycerol, 3% SDS, 0.0001% Bromophenole blue; for reducing 
buffer: + 5% β-Mercaptoethanol 
SDS-PAGE running buffer 25 mM Tris, 192 mM Glycine , 0.1% w/v SDS, (pH 8.3) 
TAE buffer  40 mM Tris-acetate, 1 mM EDTA, (pH 8.0) 
TBS buffer 50 mM Tris-HCl, 150 mM NaCl, (pH 7.4) 
Western blot transfer buffer 25 mM Tris, 192 mM Glycine, 20% v/v Methanol, (pH 8.3) 
2x HBS buffer  50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4, (pH 7.05) 
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2.1.12 Protein purification buffers 
protein purification Binding buffer components Elution buffer components 
His-tag, human-IgG1 50 mM NaH2PO4, 300 mM NaCl, 
10 mM Imidazol, (pH 8.0) 
50 mM NaH2PO4, 300 mM NaCl, 250 
mM Imidazol, (pH 8.0) 
Protein A, human-IgG1 100 mM Tris/HCl, (pH 8.0)     100 mM Glycine, (pH 3.0) 
Protein A, mouse IgG1 3 M NaCl, 1.5 M Glycine, (pH 8.9) 100 mM Glycine, (pH 3.0) 
Strep-tag 
 
100 mM Tris/HCl, 150 mM NaCl,  
1 mM EDTA, (pH 8.0) 
100 mM Tris/HCl, 150 mM NaCl, 1 mM 
EDTA, 2.5 mM Desthiobiotin, (pH 8.0) 
2.1.13 Kits 
Kit  Source 
Annexin V-FITC/7-AAD kit Beckman Coulter 
Cell Proliferation kit I (MTT) Roche 
Experion Pro260 kit Bio-Rad 
GeneMorph II Random Mutagenesis kit Stratagene 
Human NK cell isolation kit Miltenyi Biotec 
NucleoBond® Xtra Maxi MACHEREY-NAGEL 
NucleoSpin® Plasmid QuickPure MACHEREY-NAGEL 
OneStep RT-PCR kit Invitrogen 
QIAquick Gel Extraction kit Qiagen 
RNeasy Midi kit  Qiagen 
2.1.14 Special laboratory chemicals and equipments  
Chemicals/equipments Source 
ABTS  Roche 
Agarose for DNA-electrophoresis Carl Roth  
Blotting Grade Blocker Non-Fat-Dry Milk Bio-Rad 
Chloroquine Sigma-Aldrich 
Dialysis membrane  Carl Roth 
D-Sorbitol Sigma-Aldrich 
Ethanol BÜFA 
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Extra Thick Blot Paper Protean XL Size Bio-Rad 
Glycine Carl Roth 
HisTrap™ HP Columns (1 ml) GE Healthcare 
HiTrap™ Protein A HP Columns (1 ml) GE Healthcare 
Imidazole Carl Roth 
Immun-blot PVDF membrane  Bio-Rad 
Methanol Merck 
Mineral oil Fulka 
N-Butanol Carl Roth 
OptiPhase Supermix PerklinElmer 
Sodium chloride Carl Roth 
Strep-Tactin, Superflow Cartridge (1 ml) Qiagen 
Sucrose Sigma-Aldrich 
SuperSignal West Dura Extended Duration Substrate Pierce 
Triton X-100 Merck 
Tween 20 Merck 
β-Mercaptoethanol  Sigma-Aldrich 
2-Propanol (Isopropanol) Carl Roth 
2.1.15 Plastic wares 
Plastic wares  Source 
ADCC plates: 96-well plate round bottom with lid Sarstedt 
Agar solid media dishes for E. coli culture NUNC 
Cell culture flasks and dishes  Sarstedt 
Centrifugal Filtration:  Vivaspin 6 Sartorius Stedim  
CryoPure tubes Sarstedt 
Electroporation Cuvette: 0.1 and 0.2 cm gap Bio-Rad 
Falcon tubes15 and 50 ml Sarstedt 
Rotilabo®-syringe filters Carl Roth 
Safe-lock tubes, 1 ml and 1.5 ml Eppendorf 
Stericup® Vacuum filter systems Millipore 
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Sterile Acrodisc Syringe Filters  Pall Coporation 
Vacuum filter cups: Stericup & Steriotop Millipore 
96 well plates, flat bottom for ELISA Costar 
96 well sample plate for use  with 1450 microbeta Sartorius Stedim 
2.1.16 Laboratory apparatuses 
Apparatuses Source 
Automated Cell Viability Analyzer: Vi-CELL Beckman Coulter 
Balance: TE 15025  Sartorius 
Bio vortexer Lab 4 you 
Camera  Sony 
Centrifuge: Biofug Pico (Rotor 3328) Heraeus 
Centrifuge: Megafuge 1.0 R (Rotor 2704) Heraeus 
Centrifuge: Multifuge 4 KR (Rotor LAC-250) Heraeus  
Centrifuge: Sorvall RC-6 (Rotor SS-34) Thermo Scientific 
CO2 incubator: HERAcell 240  Thermo Scientific 
Electrophoresis cell: Mini-PROTEAN 3  Bio-Rad 
Electrophoresis power supply: E143 Consort 
ELISA reader TECAN 
Experion™ Automated Electrophoresis System Bio-Rad 
Flow cytometer: Cytomics FC 500  Beckman Coulter 
Galaxy mini microcentrifuge VWR 
Gel documentation system: E.A.S.Y. 440k Herolab 
Heraeus Function Line Incubators Thermo Scientific 
Incubation Shakers: CERTOMAT® BS-T   Sartorius Stedim 
Inverted microscope: Axiovert 40 C Zeiss 
Magnetic stirrer: RCT basic IKA 
Microplate scintillation and luminescence counter: 
MicroBeta® TriLux 
PerkinElmer 
Microlitre centrifuge   Heraeus 
Microplate reader: TECAN infinite M200  TECAN 
MicroPulser Electroporation Apparatus Bio-Rad 
2. MATERIALS & METHODS     
 34 
PH meter: PH 2111 Microprocessor  HANNA 
Power supply: PowerPac HC Bio-Rad 
Protein purifier: ÄKTApurifier GE Healthcare 
Scanner: ScanMaker 9800XL Microtek 
Sonicator: Sonopuls  Bandelin 
Sterile bench: HERAsafe Heraeus 
Thermocycler: PTC200  MJ Research 
Thermomixer comfort  Eppendorf 
Trans-Blot SD: Semi-Dry Transfer Cell  Bio-Rad 
Tube Roller Mixer: SRT1 Stuart 
Upright microscopes: Axiostar plus Zeiss 
Vacuum pump KNF Neuberger 
Vacuum pump: ECOM-P 4153 Eppendorf 
Wallac MicroBeta TriLux detector PerkinElmer 
Waterbath  Memmert 
Western blot digital imaging system: ChemiDocXRS  Bio-Rad 
2.1.17 Computer software 
Software Source 
Fc 500 CXP  Beckman Coulter 
GraphPad Prism 4.0 GraphPad Inc. 
Quantity One Bio-Rad 
Vector NTI Invitrogen 
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2.2 Methods 
2.2.1 Cell biological methods 
2.2.1.1 Culture of adherent cells 
TH-111 hybridoma cells grew adherent. These cells were cultured in RPMI1640 
medium containing 10% FBS (heat-inactivated at 56 °C for 30 min) and 1% 
Pen/Strep at 37 °C with 5% CO2 in a humidified incubator. The cell density was about 
2-3 x 106 cells/80 cm2. These cells secreted the CD96 monoclonal antibody into the 
medium. Every two days, the cell flask was rinsed with PBS and incubated with 
trypsin-EDTA solution until the cells were detached (not more than 5 min). Following 
the cells detachment, 10 ml prewarmed RPMI1640 medium was added to neutralize 
the trypsin solution. The cell suspension was centrifuged at 300 x g in a Megafuge 
1.0 R (Rotor 2704) for 5 min. A part of cell pellet was resuspended in a new tissue 
culture flask with prewarmed fresh medium and the rest of cells were frozen. The cell 
pellet was resuspended in a solution of 10% DMSO/FBS with a concentration of 
about 2-3 x 106 cells/ml. Aliquots of 1 ml were frozen in cryovials and stored first at -
80 °C and placed later in liquid nitrogen. 
2.2.1.2 Culture of suspension cells 
HSB-2 and KG1a cells are suspension cells. These cells were cultured in RPMI1640 
medium containing 10% FBS and 1% Pen/Strep at 37 °C with 5% CO2 in a humidified 
incubator. The cell density was about 0.3-0.4 x 106 cells/ml. The cells were 
centrifuged at 300 x g in a Megafuge 1.0 R (Rotor 2704) for 10 minutes to spin down 
the cells every two days and the medium was replaced with fresh prewarmed 
medium. A part of cell pellet was frozen as described above. The other culture 
conditions were mentioned above (Table 2.1.1). 
2.2.1.3 Isolation of peripheral blood mononuclear cells using density gradient 
Citrate-anticoagulated blood, from a healthy volunteer, was layered over a 
discontinuous gradient consisting of 70% and 62% Percoll/Hank’s medium 
respectively. After brake-off/centrifugation at RT for 20 min, MNCs were collected 
from the serum/Percoll interface. To remove the platelets, the cell pellet was 
resuspended in PBS and centrifuged at 300 x g for 10-15 min at 20 °C. The cell 
pellet was subjected to a shock lysis by mixing it with 45 ml of ice-cold water for 30 s 
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followed by immediate addition of 5 ml of 10 x PBS. The supernatant was removed 
and washing was repeated. MNCs from healthy volunteers typically contained about 
60% CD3-positive T cells, 10-15% CD56-positive NK cells, and 3-10% CD14-
expressing monocytes, as determined by immunofluorescence staining. Viability of 
the cells tested by Trypan blue exclusion and in an automated cell viability analyzer 
(Vi-CELL) was higher than 95%. 
2.2.2 Molecular biological methods 
2.2.2.1 Isolation of RNA 
TH-111 hybridoma cells that express CD96 monoclonal antibody were used as a 
source of RNA for cloning of CD96 variable region genes. The RNA was isolated with 
RNeasy Midi kit according to manufacturer’s instructions which is summarized below. 
The appropriate number of cells was centrifuged at 300 x g in a Megafuge 1.0 R 
(Rotor 2704) for 5 min. All supernatant was carefully removed by aspiration. The 
cells were disrupted by the addition of 4 ml of RLT buffer and were mixed. 10 µl β-
ME per 1 ml RTL buffer was added before use. The lysate was then passed at least 
5-10 times through a 10-20 gauge needle fitted to a RNase-free syringe. 2-4 ml of 
70% ethanol was added to the homogenized lysate and mixed well by pipetting (no 
centrifugation). The sample was applied onto a RNeasy mini column placed in a 15 
ml collection tube and was centrifuged at 3000-5000 x g at 20 °C for 5 min. The flow-
through was discarded. 4 ml RW1 buffer was added to the RNeasy column and 
centrifuged at 3000-5000 x g for an additional 5 min. The flow-through and collection 
tube were discarded. 2.5 ml RPE buffer was pipetted onto the column and 
centrifuged at 3000-5000 x g for 2 min to wash the column. The flow-through was 
discarded again. 2.5 ml buffer RPE was added again to the column and centrifuged 
at 3000-5000 x g for 5 min to dry the RNeasy silica-gel membrane. The RNeasy 
column was transferred to a new 15 ml collection tube. 250 µl RNase-free water was 
pipetted directly onto the RNeasy silica-gel membrane and centrifuged at 3000-5000 
x g for 1 min. A new RNaesy column was used and the elution step was repeated 
with a second volume of RNase-free water. The product was immediately used or 
stored at -20 °C to later use. 
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2.2.2.2 Reverse Transcription of RNA to cDNA 
15 µg of total RNA was used as template for reverse transcription to cDNA with 
SuperScript™ II Reverse Transcriptase, according to manufacturer’s instructions that 
are summarized below. 2 µl oligod T was added to RNA and heated at 70 °C for 10 
min. This destabilized mRNA secondary structure. The sample was allowed to cool 
down to 4 °C. 2 µl RNAse inhibitor and 10 µl 5 x RT buffer were added. 7.5 µl 
dNTP‘s (10 mM each dATP, dCTP, dGTP, dTTP) were added. 5 µl of 0.1 M DTT and 
up to 48 µl nuclease-free water were added. 2 µl (200 U) Reverse Transcriptase (SS 
II RT) was added. The mixture was incubated at RT for 10 min and then at 42 °C for 
50 min. The reaction was terminated by incubation at 90 °C for 5 min. The 
temperature was lowered to 4 °C for 10 min. 1 µl (1 U/µl) of RNAse H was added and 
the mixture was incubated at 37 °C for 20 min. RT product was immediately used or 
stored at -20 °C to later use. A negative control (without template RNA) was also 
prepared. 
2.2.2.3 Polymerase chain reaction (PCR) of VH and VL 
PCR was performed using peqGOLD Taq DNA polymerase according to 
manufacturer’s instructions (summarized in Table 2.2.1). Appropriate components 
were applied in a sterile 0.5 ml microcentrifuge tube sitting on ice. VH and VL PCR 
were achieved in separate tubes. The content of tubes were mixed and incubated in 
a thermal cycler using the appropriate PCR condition (Krebber et al., 1997) (Table 
2.2.2). 
Table 2.2.1 Preparation of a PCR mixture 
Component PCR/volume Control/volume 
10 x PWO complete reaction buffer 5 µl 5 µl 
dNTP’s mixture (2.5 mM) 4 µl 4 µl 
MgCl2 (25 mM) 4 µl 4 µl 
LB or HB primer (100 µM) 1 µl 1 µl 
LF or HF primer (100 µM) 1 µl 1 µl 
cDNA 2 µl 0 µl 
0.5 µl Pwo (1 U/µl) and 20 µl Taq (5 U/µl) 
Polymerase mixture 
3 µl 3 µl 
sterile dH2O up to 50 µl up to 50 µl 
Total volume 50 µl 50 µl 
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Table 2.2.2 Thermal cycler conditions 
Number of cycles temperature Duration 
1 92 °C 5 min 
7 92 °C 1 min 
7 63 °C 30 s 
7 58 °C 50 s 
7 72 °C 1 min 
23 92 °C 1 min 
23 63 °C 1 min 
23 72 °C 1 min 
2.2.2.4 Analysis the amplified products (VL and VH) by electrophoresis 
All products (VL and VH) were run on a 1% agarose gel. Samples were mixed with 
1/6 volume of 6 x loading buffer and electrophoresis performed at 115 V for 30 min in 
a mini-sub cell electrophoresis tank filled with TAE buffer. Size of DNA fragments 
was identified under UV light by comparison with known DNA size marker (100 bp 
ladder) loaded in a separate well of gel.  
2.2.2.5 DNA purification 
DNA fragments were excised from the agarose gel using clean scalpels and the gel 
pieces were minimized. DNA purification was performed using Qiagen gel extraction 
kit. 500 µl of QG buffer was added to each sample and samples were incubated at 
50 °C for 10 min or until the gel slices were completely dissolved. After this 
incubation, the colour of mixture must be yellow similar to QG buffer. 150 µl 
Isopropanol was added to the samples and vortexed. A QIAquick spin column was 
placed in a provided 2 ml collection tube for every sample. The samples were applied 
to the column and centrifuged at maximum speed for 1 min. The flow-through was 
discarded and the column was placed back in the same collection tube. 750 µl PE 
buffer was added to the column and centrifuged for 1 min. The flow-through was 
discarded again and the column was centrifuged for an additional 1 min. The 
QIAquick column was placed into a clean 1.5 ml microcentrifuge tube. 50 µl of sterile 
water was added onto the centre of QIAquick membrane and the column was 
centrifuged for 1 min. All products were run on a 1% agarose gel and were identified 
by size under UV light. The fragments were purified from the gel using the Qiagen 
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extraction kit as described above. The products were immediately used or stored at -
20 °C until further use.  
2.2.2.6 Assembly of scFv by Splice Overlap Extension PCR (SOE-PCR) 
ScFvs were assembled in VL-VH orientation with a linker containing 20 amino acids,  
Glycine-Serine by SOE-PCR (Krebber et al., 1997), using peqGOLD Taq and PWO 
DNA polymerase according to manufacturer’s instructions (summarized in Table 
2.2.3). The appropriate components were applied to a sterile 0.5 ml microcentrifuge 
tube sitting on ice. The contents of the tube were mixed and incubated in a thermal 
cycler according to appropriate PCR conditions (Table 2.2.4). The PCR products 
(scFvs) were separated on a 1% agarose gel, and purified from the gel as described 
above (see 2.2.2.4). 
Table 2.2.3 Preparation of SOE- PCR mixture 
Component PCR/volume Control/volume 
10 x PWO complete reaction buffer 5 µl 5 µl 
2.5 mM dNTP’s mixture 4 µl 4 µl 
Scfor primer (50 µM) 0.5 µl 0.5 µl 
Scback primer (50 µM) 0.5 µl 0.5 µl 
0.5 µl Pwo (1 U/µl) and 20 µl Taq (5 U/µl) 
Polymerase mixture 
3 µl 3 µl 
VL-PCR product 10 ng  0 ng  
VH-PCR product 10 ng 0 ng 
sterile dH2O up to 50 µl up to 50 µl 
Total volume 50 µl 50 µl 
Table 2.2.4 Thermal cycler conditions 
Number of cycles temperature Duration 
7 92 °C 1 min 
7 63 °C 30 s 
7 58 °C 50 s 
7 72 °C 1 min 
23 92 °C 1 min 
23 63 °C 30 s 
23 72 °C 1 min 
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2.2.2.7 Digestion of amplified scFv  
The components (Table 2.2.5) were applied and mixed in a 0.5 ml tube. The 
appropriate restriction enzyme was used, (in this case SfiI). The sample was overlaid 
with mineral oil to avoid evaporation, and incubated at 50 °C for 3-4 h. The 
appropriate amount of pAK100 vector was also digested with SfiI restriction enzyme. 
The digestion products were supplemented with 6 x DNA loading buffer, and run on 
an agarose gel. The DNA fragments were excised from the gel, and purified from the 
agarose gel, to utilize for ligation. 
Table 2.2.5 Preparation of restriction mixture 
Component Volume 
10 x enzyme buffer 2 6 µl 
100 x BSA 0.6 µl 
SfiI (20 U/µl) 1-2 µl 
PCR product 50 µl 
sterile dH2O up to 60 µl 
Total volume 60 µl 
2.2.2.8 DNA ligation 
20 ng SfiI digested scFv gene fragments were ligated into SfiI digested pAK 100 
vector (molar ratio vector to insert 3:1). The vector concentration was calculated: 
ng insert = [(*ng vector) x (kb size of insert)] : [(kb size of vector) x (molar ratio of 
insert/vector)]. The appropriate components (Table 2.2.6) were mixed in a 0.5 ml 
tube, and the mixture was incubated overnight at 16 °C. 
Table 2.2.6 Preparation of ligation mixture 
Component Volume 
10 x ligase buffer 1 µl 
T4 DNA ligase (1 U/µl)  1 µl 
Digested vector * ng 
Digested insert 20 ng 
sterile dH2O up to 10 µl 
Total volume 10 µl 
2.2.2.9 Heat-shock bacterial cell transformation 
Chemically competent E. coli cells, strain Mach1 were generally used for DNA 
transformation. One vial of E. coli was thawed on ice. 1-5 µl of ligation product, (10 
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pg-100 ng), was added to E. coli cells, and mixed gently. The E. coli vial was 
incubated on ice for 30 min. The cells were heat-shocked at 42 °C for 30 s followed 
by incubation on ice for 2 min. 250 µl of prewarmed SOC medium was added. The 
vial was sealed tightly and shaken horizontally at 37 °C for 1 h at 225 rpm in a 
shaking incubator. 25-100 µl of cells was spread on a prewarmed selective agar 
plate. The plates were inverted and incubated at 37 °C overnight. To verify the 
ligation, 10 single overnight-grown colonies were inoculated in 3 ml selective media, 
and shaken at 37 °C for about 4 h. The plasmids were isolated. 
2.2.2.10 Isolation of plasmid DNA from E. coli cells (mini preparation) 
To verify the ligation product, DNA from 10 E. coli colonies was isolated using 
NucleoSpin® Plasmid Quick Pure kit. 1.5 ml of a saturated E. coli cells, from 
overnight-grown colonies, were transferred into a microtube and centrifuged for 3 min 
at maximum speed. The supernatant was discarded. 250 µl A1 buffer was added and 
the cell pellet was resuspended by vigorous vortexing. 250 µl A2 buffer was added 
and mixed gently by inverting the tube 6-8 times, and incubated at RT for a maximum 
of 5 min. 300 µl A3 buffer was added and mixed gently by inverting the tube 6-8 
times. The mixture was centrifuged for 5 min at maximum speed at RT. A 
NucleoSpin® Plasmid QuickPure column was placed in a 2 ml collecting tube and 
700 µl supernatant was loaded onto the column. The column was centrifuged for 1 
min at maximum speed and the flow-through was discarded. The column was placed 
back into the 2 ml collecting tube and 450 µl AQ buffer was added and centrifuged 
for 1 min. Flow-through was discarded. The column was dried out by centrifugation 
for 3 min. The column was placed in a 1.5 ml microcentrifuge tube. 50 µl sterile dH2O 
was added and incubated for 1 min at RT. The column was centrifuged for 1 min. 
The isolated DNA was digested with appropriate enzyme (SfiI) as described above. 
Digested DNA was supplemented with DNA loading buffer and run on an agarose 
gel. The size of DNA fragments (insert and vector) were identified under UV light by 
comparison with DNA size marker.  
2.2.2.11 Isolation of plasmid DNA from E. coli cells (maxi preparation) 
Purification of a large amount of plasmid was utilized using a NucleoBond® Xtra 
Maxi kit. 200 ml of a saturated E. coli cells from the overnight-grown colony was 
centrifuged at 4 °C. The bacterial cell pellet was resuspended in 12 ml of RES buffer 
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(RNase was added to RES buffer before use) by pipetting up and down. 12 ml of 
lysis buffer, LYS was added to the suspension and mixed gently by inverting the tube 
5 times. The mixture was incubated at RT for 5 min. A NucleoBond® Xtra column, 
together with the inserted column filter, was equilibrated with 25 ml of equilibration 
buffer, EQU. 12 ml of neutralization buffer, NEU, was added to the suspension and 
the lysate was gently mixed by inverting the tube 10-15 times. The lysate was 
simultaneously cleared and loaded onto the column. The NucleoBond® Xtra column 
filter, and NucleoBond ® Xtra column, were washed with 15 ml of EQU buffer. The 
NucleoBond® Xtra column filter was discarded. The NucleoBond® Xtra column was 
washed with 25 ml of washing buffer, and the plasmid DNA was eluted with 15 ml of 
elution buffer, ELU. The eluate was collected in a 15 ml or 50 ml centrifuge tube 
which was appropriated for high speed centrifugation. 10.5 ml of Isopropanol was 
added to the precipitate of eluted plasmid DNA. The tube was vortexed well and then 
was incubated at RT for 2 min. The tube was centrifuged at 5000 x g in a Sorvall RC-
6 centrifuge (Rotor SS-34) at 4°C for 30 min. The supernatant was carefully 
discarded. 5 ml of 70% Ethanol was added to the pellet and the tube was centrifuged 
at 5000 x g for 5 min at RT. The ethanol was carefully removed from the tube and the 
pellet was air-dried. The DNA pellet was dissolved in 500 µl sterile dH2O and 
concentration of plasmid was determined using a biophotometer. 
2.2.2.12 Preparation of electro-competent of E. coli cells 
A single colony from an E. coli plate was inoculated into 10 ml 2xYT medium 
containing the appropriate antibiotic of the E. coli strain (40 µg/ml Tet for XL-1 Blue 
strain), and incubated at 37 °C overnight in a shaking incubator. 2.5 ml of this 
overnight culture was added into 0.5 ml 2xYT containing 20% glucose and 5 ml 1M 
MgCl2. The culture was incubated at 37 °C for about 4 h in the shaking incubator until 
an OD600 of 0.7-0.8. The E. coli cells were chilled on ice for 15 min and then were 
centrifuged at 4 °C at maximum speed, in a Megafuge 1.0 R (Rotor 2704) for 20 min. 
The pellet was resuspended in a half volume of pre-chilled 10% glycerol (500 ml for 1 
L culture), and was centrifuged at 4 °C for 20 min. The pellet was resuspended again 
in a half volume of glycerol and centrifuged for an additional 20 min. The pellet was 
resuspended in 25 ml Glycerol and centrifuged for 15 min. The cell suspension was 
filled as 50 µl aliquots into eppendorf tubes. The tubes were shock-frozen in liquid 
Nitrogen. These aliquots were finally stored at -80 °C. 
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2.2.2.13 DNA precipitation 
DNA precipitation was performed to remove the salt from the ligation mixture, to 
improve the electroporation efficiency and reduce the arcing risk in electroporation 
cuvettes. The sterile dH2O was added to increase the volume of the ligation mixture 
to 50 µl. 500 µl n-Butanol was added and vortexed for 20 s. The sample was 
centrifuged at maximum speed in a Microfuge for 15-20 min. The DNA pellet was air 
dried and subsequently resuspended in 10 µl sterile dH2O to use for electroporation. 
2.2.2.14 Electroporation of E. coli cells 
One vial of electrocompetent XL1-Blue E. coli was thawed on ice. The ligation 
mixture was precipitated and desalinated as described above. 1 µl of desalinated 
ligation mixture was added into a vial of E. coli cells and mixed gently. 40-80 µl of 
mixture was transferred into a pre-chilled electroporation cuvette with 0.1 cm gap. 
Electroporation was achieved using a MicroPulser electroporation apparatus under 
the condition of 1800 V. 1 ml of prewarmed SOC medium was immediately added to 
each vial. The vial was sealed tightly and shaken horizontally at 37 °C for 1 h at 225 
rpm in a shaking incubator. 25-100 µl of the electroporation mixture was spread on a 
prewarmed 2xYT agar plate containing 1% glucose and the appropriate antibiotic. 
The plate was incubated overnight at 37 °C. The electroporation procedure was 
repeated for a large library construction. 
2.2.2.15 Mutagenesis-PCR of scFv 
The first approach to improve the functional characteristics of the scFv was 
attempted by introducing random mutations over the entire gene coding for the scFv 
by error-prone PCR, using the GeneMorph II Random Mutagenesis kit as described 
by manufacturer’s instructions (summarized in Table 2.2.7 and 2.2.8). The PCR 
condition was utilized to obtain 0-4 mutations per 1000 base pairs (Table 2.2.9).  
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Table 2.2.7 Preparation of Mutagenesis-PCR reaction mixture  
Component PCR/volume Control/volume 
10 x Mutazyme II reaction buffer 5 µl 5 µl 
40 mM dNTP’s mixture (10 mM each) 1 µl 1 µl 
Mut-Scfor primer (1µg/µl) 2.5 µl 2.5 µl 
Mut-Scback primer (1µg/µl) 2.5 µl 2.5 µl 
Mutazyme II DNA polymerase (2.5 U/µl) 1 µl 1 µl 
Template DNA 10 µl 0 µl 
sterile dH2O up to 50 µl up to 50 µl 
Total volume 50 µl 50 µl 
Table 2.2.8 Thermal cycler conditions 
Number of 
cycles 
temperature Duration 
1 95 °C 2 min 
 
30 
95 °C 
Primer Tm-5 °C 
72 °C 
30 s 
30 s 
1 min 
1 72 °C 10 min 
Table 2.2.9 Determine the frequency of mutation 
Mutation rate Mutation frequency 
(Mutations/kb) 
Initial target amount 
(ng) 
Recommended fold 
amplification 
Low 0-4.5 500-1000 1.5-10 
Medium 4.5-9 100-500 10-100 
High 9-16 0.1-100 100-10000 
2.2.2.16 OneStep RT-PCR for CD96-ECD construction 
Total RNA was isolated from CD96-positive HSB-2 cells using RNeasy Midi kit 
according to manufacturer’s instructions and as described previously. A master 
mixture for OneStep RT-PCR was prepared (Table 2.2.10). A negative control, 
(without template RNA), was also prepared. The master mixture was mixed 
thoroughly by pipetting and appropriate volumes were dispensed into PCR tubes. 
The samples were incubated in a thermocycler using the appropriate PCR condition 
(Table 2.2.11).  
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Table 2.2.10 Reaction components for one-step RT-PCR of ECD 
Component PCR/volume  Control/volume 
5 x OneStep RT-PCR buffer 10 µl 10 µl 
dNTP  mixture (10 mM each) 2 µl 2 µl 
ECD-For primer (100 µM/µl) 1 µl 1 µl 
ECD-Rev primer (100 µM/µl) 1 µl 1 µl 
OneStep enzyme mixture 2 µl 2 µl 
Template RNA 1 µl 0 µl 
RNase-free water up to 50 µl up to 50 µl 
Total volume 50 µl 50 µl 
Table 2.2.11 Thermal cycler conditions 
Cycles  
25-40 
temperature Duration 
Reverse transcription 50 °C 30 min 
Initial PCR activation step 95 °C 15 min      
Denaturation 94 °C 0.5-1 min 
Annealing 55-68 °C 0.5-1 min 
Extension 72 °C 1 min 
Final extension 72 °C 10 min 
The PCR product was run on a 1% agarose gel and was identified by size under UV 
light. The product was purified from the gel as described before (see 2.2.2.5). CD96-
ECD was digested with NheI and NotI restriction enzymes. NheI and NotI digested 
CD96-ECD was cloned into NheI and NotI digested pSEC-IgG1-Fc vector, resulting 
pSEC-CD96-ECD-IgG1-Fc. 293T cells were transient and stably transfected with 
pSEC-CD96-ECD-IgG1-Fc. The supernatant was collected. The purified CD96-ECD-
IgG1-Fc protein was analyzed by SDS-PAGE with Coomassie staining and western 
blot. 
2.2.3 Phage display recombinant antibody system 
2.2.3.1 Infection of E. coli cells with helper phages 
XL1-Blue colonies were washed off with 2xTY medium from the transformation 
plates. 100 µl of bacterial cell suspension was applied to 100 ml 2xTY medium 
containing 1% glucose and 30 µg/ml chloramphenicol. The suspension was 
incubated at 37 °C in a shaking incubator until the culture density reached an OD600 
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of 0.7. This OD is equivalent to 5.6 x 108 bacteria/ml. The culture was infected with 
helper phages, M13KO7 (1012 pfu/ml) and incubated at 37 °C without shaking for 30 
min. 200 ml of 2xYT medium containing 1% glucose and 30 µg/ml chloramphenicol 
was added. IPTG was supplied at a final concentration of 0.5 mM. The culture was 
incubated at 37 °C for 1 h under vigorous shaking. After 1 h, kanamycin was added, 
(final concentration of 25 µg/ml), and the culture was incubated at 30 °C overnight in 
the shaking incubator. 
2.2.3.2 Preparation of phages 
The overnight culture was centrifuged at maximum speed in a Megafuge 1.0 R 
(Rotor 2704) at 4 °C for 15 min. The supernatant was transferred to a new tube. The 
phages were precipitated with ¼ volume of polyethylene glycol, (20% PEG 6000 + 
2.5 M NaCl), on ice for 30 min and were subsequently centrifuged at 10.000 x g in a 
Sorvall RC-6 (Rotor SS-34) centrifuge at 4 °C for 20 min. The supernatant was 
removed and the pellet was air-dried. The cell pellet was resuspended in 2 ml PBS 
buffer and was centrifuged at maximum speed for 5 min. The supernatant was stored 
at 4 °C until use. 
2.2.3.3 Estimation of phage titration 
50 µl of TG1 E.coli cells was added to 25 ml 2xTY medium and incubated at 37 °C 
for 2 h under vigorous shaking. The phage preparation (from step 2.2.3.2) was 
diluted (10-3, 10-6, and 10-9) in order to estimate the titration of eluted phages. 1 µl of 
each dilution was added to 100 µl of E. coli cells, and incubated at 37 °C for 30 min 
without shaking. The aliquot of each tube was spread on three agar plates containing 
1% glucose, 30 µg/ml chloramphenicol and incubated at 37 °C overnight. The 
number of bacterial colonies on each plate was counted. The phage titration was 
calculated by the multiplication of colonies formed with the dilution factor.  
2.2.3.4 Screening of library for binders on intact tumor cells 
5 x 106 CD96-positive cells (HSB-2 cells) were blocked with 500 µl of 4% NM/PBS at 
RT for 30 min under slow agitation. 500 µl of phage suspension was added and 
incubated at RT for 1.5-2 h under slow agitation. The HSB-2 cells were rinsed 10 
times with 5 ml of 2% NM/PBS and twice with 5 ml PBS. Bound phages were eluted 
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by incubation with 1.5 ml of 50 mM HCl for 10 min. After neutralization with 500 µl of 
1 M Tris at pH 7.5, the cells were pelleted by centrifugation. The supernatant was 
utilized to infect 10 ml growing TG1 cells at 37 °C for 30 min. 20 ml of 2xYT medium 
containing 1% glucose and 30 µg/ml chloramphenicol was added to the culture and 
the culture was incubated at 37 °C for 2 h under vigorous shaking. The cells were 
super-infected with 1 ml of 1 x 1012 pfu/ml of helper phages at 37 °C for 30 min 
without shaking. The IPTG concentration was adjusted to 0.5 mM. 100 ml of 2xYT 
medium containing 1% glucose and 30 µg/ml chloramphenicol was added. 1 h after 
the infection, kanamycin was added at a final concentration of 25 µg/ml. The culture 
was incubated at 30 °C overnight in a shaking incubator. On the following day, the 
phages were prepared as described before (see 2.2.3.2) and the screening was 
repeated 3 times. 
2.2.3.5 Screening the library for binders on ECD protein 
The scFv product from mutagenesis-PCR was also applied to produce a phage 
library and a library with about 1 x 106 independent colonies was generated. The 
phages were selected by binding to CD96-ECD protein. Briefly, 10 µg/ml of CD96-
ECD was utilized to coat the ELISA plates at 4 °C overnight. In each round of 
selection, 1 x 1012 bacteriophages were used as input. After 2 h of incubation at RT, 
the plates were rinsed 20 times with PBS supplemented with 1% Triton X-100 and 
1% Tween 20. The plates were rinsed also 10 times with PBS. The washing process 
was optimized to complete elimination of wild type scFv-expressing bacteriophages. 
Bound phages were eluted and immediately neutralized as described before. After 
the fifth round of screening, 30 individual colonies were randomly picked and 
sequenced in comparison to the same number of colonies from the original library. 
2.2.3.6 Estimation of eluted phage titration  
1 µl and 10 µl of eluted phages were applied to 100 µl of cultivated TG1 E.coli cells 
and incubated for 30 min at 37 °C without shaking. Aliquot of each dilution was 
spread on agar plates containing 1% glucose and 30 µg/ml chloramphenicol. These 
plates were incubated overnight at 37 °C. The bacterial colonies on each plate were 
counted. The titre was calculated by multiplication of colonies formed with the dilution 
factor. 
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2.2.3.7 Whole cell-phage ELISA  
Cellular ELISA was performed with CD96-positive cells (HSB-2) to show the binding 
activity of scFv-expressing bacteriophages to CD96 antigen. CD96-negative cells 
(CEM) were utilized as negative control. 1 x 106 cells per well were blocked with 100 
µl of 2% NM/PBS in a 96-well plate at RT for 1 h under slow agitation. After 1 h, the 
cells were centrifuged and resuspended in 50 µl phages supernatant supplemented 
in 1% NM/PBS. The plate was incubated at RT for 1-1.5 h under slow agitation. The 
cells were rinsed five times with 0.1% NM/PBS and twice with PBS. The cells were 
incubated with 50 µl of 1:2000 of anti-M13 HRP-conjugated antibody/1% NM/PBS 
per each well at RT for 1 h under slow agitation. The plate was again rinsed three 
times with 0.1% NM/PBS and twice with PBS. Detection was performed with 80 µl of 
freshly prepared ABTS substrate. The absorbance was scanned at A = A (405 nm) - 
A (492 nm). 
2.2.3.8 Preparation of monoclonal phage  
To identify the ability of single phage colonies to recognize the CD96 antigen, 10 
individual colonies were inoculated from the titre plates following last screening into 2 
ml 2xTY medium, containing 1% glucose and 30 µg/ml chloramphenicol, and  
incubated at 37 °C for 6-8 h in a shaking incubator. 100 µl helper phages were 
applied into the bacterial culture and incubated at 37 °C for 30 min without shaking. 
20 ml of 2xTY medium containing 1% glucose and 30 µg/ml chloramphenicol 
together with 0.5 mM IPTG were added. After 1 h incubation at 37 °C, 4 ml medium 
containing glucose and chloramphenicol was added. Kanamycin was subsequently 
supplied at a final concentration of 25 µg/ml, and the culture was incubated at 30 °C 
overnight. The overnight culture was centrifuged at 4 °C for 15 min. The phages were 
precipitated with ¼ volume polyethylene glycol (20% PEG 6000 + 2.5 M NaCl) on ice 
for 30 min, and then were centrifuged at 10.000 x g in a Sorvall RC-6 (Rotor SS-34) 
centrifuge at 4 °C for 20 min. The cell pellet was air-dried and was resuspended in 
400 µl PBS. The suspension was centrifuged at maximum speed for 5 min. The 
supernatant was stored at 4 °C until use. Individual phage colonies were tested in 
ELISA as described above (see 2.2.3.7) to determine of their ability to recognize the 
CD96 antigen. 
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2.2.4 Protein expression  
2.2.4.1 Expression and purification of soluble scFv from HB2151 E. coli cells 
For soluble expression of scFv fragments in HB2151 E. coli cells, bacterial 
expression vector pAK400 and scFv were digested with SfiI restriction enzyme. The 
SfiI digested scFv was ligated into SfiI digested pAK400 vector. The plasmids were 
propagated in HB2151 cells, and the E. coli cells were spread on the agar plates 
containing 1% glucose, 30 µg/ml chloramphenicol, and incubated at 37 °C overnight. 
A single colony from the E. coli plate was inoculated into a 50 ml 2xYT medium 
containing 1% glucose and 30 µg/ml chloramphenicol and incubated at 37 °C 
overnight in a shaking incubator. The overnight culture was diluted in a 500 ml 2xYT 
medium supplemented with 1% glucose and 30 µg/ml chloramphenicol. The cultures 
were grown at 37 °C to an OD600 of 0.8 and expression was induced by adding IPTG 
at a final concentration of 1 mM, and lowering the temperature to 30 °C. After 3 h, the 
bacteria were collected by centrifugation. The cells pellet was resuspended in 50 ml 
periplasmic extraction buffer, (without EDTA), and was mixed on a magnetic stirrer at 
4 °C for 30 min. The cells were disrupted with an ultrasonic cell disruptor. The 
supernatant was passed through a cell culture filter, and centrifuged at 5000 x g in a 
Sorvall RC-6 (Rotor SS-34) centrifuge at 4 °C for 45 min. Purification of 6 x His 
tagged scFv fragments has been achieved with IMAC affinity chromatography. 
2.2.4.2 Expression and purification of soluble scFv from BL21 (DE3) E. coli 
cells  
For the soluble expression of scFv fragments in BL21 (DE3) bacteria, expression 
vector pET27b-STREP-His and scFv were digested with SfiI restriction enzyme. The 
scFv was ligated into vector pET27b-STREP-His. pET27b-STREP-His-CD96 was 
propagated in BL21 (DE3) cells. Overnight cultures were diluted in a 500 ml 2xYT 
medium supplemented with 1% glucose and 30 µg/ml chloramphenicol. The cultures 
were grown to an OD600 of 0.8-1 at 37 °C, and protein expression was induced by 
adding IPTG at a final concentration of 0.2 mM and lowering the temperature to 24 
°C. After 20 h, the bacteria were collected by centrifugation. The cells pellet was 
resuspended in a 50 ml periplasmic extraction buffer and was mixed on a magnetic 
stirrer at 4 °C for 30 min. The cells were disrupted with an ultrasonic cell disruptor. 
The cells were centrifuged at 5000 x g in a Sorvall RC-6 (Rotor SS-34) centrifuge at 
4 °C for 45 min. The supernatant was passed through a cell culture filter and 
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purification of Strep-tagged scFv fragments was achieved with Strep-tag affinity 
chromatography following with IMAC Affinity chromatography. The final elution peaks 
were concentrated and analyzed by SDS-PAGE, and capillary electrophoresis was 
used to determine amount and purity of the recombinant protein. 
2.2.4.3 Production of Fc fusion protein by transient transfection of 293T cells 
(calcium phosphate transfection)  
The CD96-scFv isolated from the initial phage display library or from the diversified 
library were digested with SfiI and cloned into into pSEC-IgG1-Fc or pSEC-IgG1-Fc-
eng vectors resulting pSEC-scFv-IgG1-Fc or pSEC-scFv-IgG1-Fc-eng (carrying a Fc 
variant optimized for CD16a binding; mutations: S239D/I332E/A330L) (Lazar et al., 
2006; Repp et al., 2010).The sequence was confirmed by Sanger sequencing of the 
final construct to confirm the expected sequence arrangement. 293T cells were 
transfected with the respective expression vector using the calcium phosphate 
transfection system, including Chloroquine. 3-5 x 106 293T cells were grown in 100 
mm tissue culture dishes overnight. After 24 h, the medium was removed and 8 ml 
prewarmed medium was added. DNA mixture was prepared: 20 µg plasmid DNA in 
895 µl sterile water + 100 µl 2.5 M CaCl2 + 5 µl 100 mM Chloroquine according to 
established procedures (Kellner et al., 2010). All amounts and volumes are given on 
a per plate basis. The DNA mixture was added dropwise to the 2 x HBS buffer while 
simultaneously introducing bubbles via continuous pipetting of air through the 
solution. The mixture was vortexed shortly and 2 ml of the transfection solution was 
added dropwise to each tissue culture plate. The plates were incubated 9-10 h at 37 
°C and 5-6% CO2 in a humidified incubator. The transfection medium was changed 
by prewarmed tissue culture medium. The supernatants were collected every 24 h 
for 7 days. The collected supernatants were either used directly for 
immunofluorescence staining or applied for protein purification. The proteins were 
purified using ÄKTA-purifier by two-step affinity chromatography, using protein A 
affinity chromatography followed by IMAC Affinity chromatography according the 
manufacturer’s instructions. The final elution peaks were concentrated, dialyzed 
against PBS buffer, and analyzed by SDS-PAGE to determine amount and purity of 
the recombinant proteins. 
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2.2.4.4 Generation of stably transfected 293T cells for expression of Fc fusion 
protein  
293T cells were stably transfected to expression Fc fusion protein. All amounts and 
volumes are given on a well basis. The day before transfection, 5 x 105 cells were 
grown in 3 ml D10+ per well in a 6-well plate. After 24 h, the medium was replaced 
with 3 ml prewarmed fresh medium. For each well 2-3 µg of DNA was diluted in 500 
µl of Opti-MEM medium. 6.5 µl of Lipofectamine LTX reagent was added into the 
above diluted DNA solution and mixed gently and incubated at RT for 30 min to form 
DNA-Lipofectamine LTX reagent complexes. After a 30 min incubation, the solution 
was added directly to each well and mixed gently. The cells were incubated at 37 oC 
in a humidified incubator for 48 h. After incubation time, the growth medium was 
replaced with fresh medium containing the selection medium, 100 µg/ml of 
Hygromycin B. The selection was continued for about 1 week until mid-sized colonies 
grew out. The cells were then trypsinized and cultivated through screening single 
cells by limiting dilution in a 96-well plate (1 cell/well) for 2 weeks. The supernatant of 
tissue cultures from every well were tested by ELISA to select the positive colonies.  
2.2.4.5 Single cell screening using ELISA 
A 96-well flat bottom plate was coated with 25 µl/well of 5 µg/ml anti-His or anti-myc 
(9E10) antibodies in PBS, and incubated at 4 °C overnight. On the following day, the 
reactions were blocked with 100 µl 3% BSA/PBS per well at RT for 1 h under slow 
agitation. The wells were washed three times with 125 µl PBS/well. To detect the Fc 
portion of scFv-Fc protein, anti-Human IgG HRP conjugated antibody was added at a 
dilution of 1:5000 in 1% BSA/PBS at RT for 1 h under slow agitation. The wells were 
washed three times with 125 µl PBS/well. The ELISA was developed with 50 µl/well 
ABTS solution and OD was measured at A = A (405 nm)-A (492 nm). The colonies 
with highest signals were selected and cultivated in a small tissue culture flask. 
2.2.5 Biochemical methods 
2.2.5.1 Tris/Glycine SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
The protein electrophoresis was performed as described by Laemmli (Laemmli, 
1970). The concentration of separating gel varies from 6 to 15% according to the 
molecular weight of proteins, while the concentration of the stacking gel is usually 
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3.6-5%. The appropriate components for separating gel were prepared (Table 
2.2.12). After pouring the separating gel up ¾ of plates, ethanol was added on the 
top of the separating gel to produce a smooth surface. Before adding the stacking 
gel, ethanol was poured off and excess ethanol was removed from the surfaces. The 
stacking gel (Table 2.2.13) was poured to the top of separating gel and the comb 
was inserted between the plates. The comb was removed after 20 min. The samples 
were diluted 1:4 in 5 x SDS-PAGE loading buffer and heated at 95 °C for 3 min. The 
serial dilutions of BSA were used as control to determine the concentration of 
appreciated molecule. The electrophoresis was carried out at 100 V in stacking gel, 
and 150 V in separating gel for approx. 1 h in SDS-PAGE running buffer.  
Table 2.2.12 Separating gel 
Component  6% 8% 10% 12% 15% 
TEMED 0.008 ml 0.006 ml 0.004 ml 0.004 ml 0.004 ml 
10% APS 0.1 ml 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
10% SDS 0.1 ml 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
1.5 M Tris (pH 8.8) 2.5 ml 2.5 ml 2.5 ml 2.5 ml 2.5 ml 
30% Acrylamide mixture 2 ml 2.7 ml 3.3 ml 4 ml 5 ml 
dH2O  5.3 µl 4.6 µl 4 µl 3.3 µl 2.3 µl 
Total volume 10 ml 10 ml 10 ml 10 ml 10 ml 
Table 2.2.13 Stacking gel 
Component  Volume 
TEMED 0.003 ml 
10% APS 0.03 ml 
10% SDS 0.03 ml 
0.5 M Tris (pH 8.8) 0.76 ml 
30% Acrylamide 
mixture 
0.5 ml 
dH20 1.34 µl 
Total volume 3 ml 
2.2.5.2 Western blot of scFv-IgG1-Fc, mouse-IgG1-Fc, and ECD-IgG1-Fc 
Following SDS-PAGE, the gels were electroblotted to PVDF membrane as described 
by Towbin (Towbin et al., 1979). The membrane was incubated in methanol followed 
by incubation in western blot transfer buffer for 5 min. The proteins were electro-
transferred to a PVDF membrane using Semi-Dry Transfer Cell with the current of 50 
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mA or 15 V for 60 min. The membrane was blocked with 5% NM/TBS buffer at 37 °C 
for 1 h. For scFv-IgG1-Fc and ECD-IgG1-Fc, the PVDF membranes were incubated 
in 1:5000 of anti-human IgG HRP conjugated antibody in blocking solution at RT for 
1 h. For mouse-IgG1-Fc protein, anti-mouse IgG HRP-conjugated antibody was 
utilized in same dilution at RT for 1 h. The membranes were rinsed with 0.1% Tween 
20/TBS, 3 times for 10 min. The proteins were detected with SuperSignal West Dura 
substrate and analyzed by a digital imaging system. 
2.2.5.3 Western blot of scFv fragments  
The protein was electro-transferred from the gel to the PVDF membrane as 
described above. The membrane was blocked with 3% BSA/TBS buffer at 37 °C for 
1 h. The membrane was incubated in Penta-His antibody which was diluted 1:1000 in 
blocking solution at RT for 1 h. The membrane was washed 3 times for 10 min with 
wash buffer (0.05% Tween 20/0.2% Triton X-100/TBS). The PVDF membrane was 
incubated with 1:5000 of anti-mouse IgG HRP-conjugated antibody in 10% NM/TBS 
at RT for 1 h. The membrane was washed again 3 times for 10 min. The protein was 
detected with SuperSignal West Dura substrate and analyzed by a digital imaging 
system.  
2.2.5.4 Analysis of CD96-ECD-IgG1-Fc by ELISA 
A 96-well ELISA plate was coated with 50 µl of the CD96 parental antibody (TH-111) 
or an irrelevant antibody (TH-69) (50 µg/ml in PBS) at 37 °C for 1 h. The wells were 
blocked with 150 µl of 3% BSA/PBS for 1 h at 37 °C. Blocking solution was replaced 
by 50 µl of 10 µg/ml soluble CD96-ECD-IgG1-Fc in blocking buffer and incubated at 
RT for 1 h. The wells were washed 3 times with 150 µl of 1% BSA/PBS and 
incubated with a goat anti-Human IgG HRP conjugated antibody. The ECD protein 
was detected with 50 µl of ABTS substrate and was analyzed in an ELISA reader. 
Results were expressed as A = A (405 nm)-A (492 nm). 
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2.2.6 Antibody effector mechanisms 
2.2.6.1 Flow cytometry 
To monitor binding of antibody-derivatives to antigen-positive cells, 5 x 105 cells were 
incubated with serial dilutions of the appropriate antibody. The unbound antibody 
was removed by washing twice with 1% BSA/PBS. The cells were stained with 1:20 
appropriate FITC-labeled antibody at 4 °C for 30 min. After 30 min, the cells were 
washed once with 1% BSA/PBS. The cells were resuspended in PFA fixation buffer 
and analyzed on a Cytomics FC500 flow cytometer using the CXP software. Ten 
thousand events were collected for each sample.  
2.2.6.2 Binding competition of the CD96 recombinant mini-antibody and the 
CD96 parental antibody (TH-111) to the CD96 antigen 
To investigate competitive binding of recombinant CD96-scFv-IgG1-Fc antibody-
derivative and the parental murine monoclonal antibody (TH-111), 5 x 105 cells were 
incubated with the antibody-derivative in the presence of a 50-fold molar excess of 
either TH-111, or an irrelevant monoclonal antibody (TH-69) at RT for 30 min. The 
cells were rinsed once with PBA and the cell pellet was resuspended in 20 µl of 1:20 
diluted of the anti-human-IgG1-FITC antibody, and incubated on ice. After 30 min, 
unbound antibodies were removed by washing with 1% BSA/PBS and the cells were 
resuspended in PFA fixation buffer and analyzed on a Cytomics FC500 flow 
cytometer using CXP software. Ten thousand events were collected for each sample. 
2.2.6.3 Antibody-Dependent Cell Mediated Cytotoxicity assay (ADCC) 
To study CD96-induced ADCC, target cells were labelled with 100 µCi of 51Cr per 1 x 
106 cells at 37 °C in a humidified CO2 incubator for 2 h. After this incubation period, 
the cells were rinsed three times with R10+ medium and incubated with serial 
dilutions of appropriate antibodies for 30 min at RT. The cells were washed once with 
10 ml R10+ medium and then adjusted to 1 x 10
5 cells/ml and added to the 96 well 
plates (50 µl/well) filled with effector cells resulting in a final volume of 200 µl.  After 3 
h incubation at 37 °C in the humidified CO2 incubator, the assays were stopped by 
centrifugation. 25 µl supernatant from each well was applied to 150 µl OptiPhase 
Supermix in a 96-well flexible plate for evaluation in a microplate scintillation and 
luminescence counter. The plate was sealed and shaken vigorously for 15 min. 51Cr 
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release from triplicates was then counted on a MicroBeta counter and measured in 
counts per minute (cpm). Maximal 51Cr release was determined by adding Triton X-
100 (1% final concentration) to target cells and spontaneous release was measured 
in the absence of effector cells. The percentage of specific lysis of labeled target 
cells was calculated using the formula:  
% specific lysis = 100 x experimental cpm - spontaneous cpm 
                                         maximal cpm - spontaneous cpm 
2.2.7 Data processing and statistical analyses 
Data is displayed graphically and statistical analyses were performed using 
GraphPad Prism 4.0 software. Dose response curves were generated. The EC50 
value (antibody concentration inducing half-maximal lysis) was calculated for each 
curve. P-values were calculated using the student’s t-test and the null hypothesis 
was rejected for p < 0.05. 
2.2.8 Homology modeling of CD96-scFv 
The three-dimensional model of the wild type CD96-scFv (CD96-wt-scFv) was 
calculated, using the Rosetta server/algorithm (Sircar et al., 2009). The surface 
display model was generated, using the Accelrys DS Viewer software. 
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3. RESULTS 
3.1 Construction of CD96-scFv  
3.1.1 Amplification of variable domains of CD96  
The total RNA was isolated from 1 x 107
 
TH-111 hybridoma cells. The isolated RNA 
was reverse transcribed into cDNA. The VH
 
and VL
 
fragments were amplified by 
PCR using the first strand cDNA as a template. The RT-PCR products were run on a 
1 % agarose gel. One prominent band of about 400 bp for the heavy and the light 
chains was visible, and no visible band was detected when H2O as control was 
utilized (Fig 3.1). The amplified VH
 
and VL
 
fragments were purified from the agarose 
gel, and the amounts of the purified fragments were calculated by agarose gel 
quantification. These fragments were applied to the assembly of the scFv gene in the 
next experiment.  
 
Fig 3.1 Amplification of CD96-VL and -VH regions. The PCR reactions were separated on a 1% 
agarose gel.  Fragment sizes are indicated in base pairs (bp). Lane 1: 100 bp-DNA Ladder, lane 2: VL 
chain, lane 3: VH chain and lanes 4, 5: negative controls. One representative experiment out of four is 
indicated.   
  
3.1.2 Assembly of scFv gene by Splice Overlap Extension, SOE-PCR 
The VH and VL DNA fragments were connected together with a (Gly4 Ser)3 linker by 
SOE-PCR (Fig 3.2). The amplified PCR product introduced the expected size of 
about 800 bp on an agarose gel, and no visible band was observed for H2O as 
negative control (Fig 3.3).  
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CD96-scFv
787 bp
CD96-VL CD96-VHGS-LinkerSfi I (9) Sfi I (783)
 
Fig 3.2 Schematic view of CD96 single chain variable fragment (CD96-scFv).  VL,  VH, and  
linker. 
 
 
 
 
 
 
 
 
 
Fig 3.3 ScFv fragments generated by SOE-PCR. The PCR reactions were separated on a 1% 
agarose gel. Fragment sizes are indicated in base pairs (bp).  Lane 1: 100 bp-DNA Ladder, lane 2: 
scFv fragment, and lane 3: negative control. One representative experiment out of four is indicated.    
3.1.3 Cloning of CD96-scFv into pAK100 phagemid vector 
The amplified scFv fragments were purified from the agarose gel. The purified 
fragments were digested with SfiI restriction enzyme. The digested scFv fragments 
were cloned into SfiI digested pAK100 phagemid vector (Fig 3.4) and transformed 
into chemically competent E. coli cells, strain Mach1.  
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CD96 scFv + pAK100
5098 bp
delta gIII
LAC I CD96-VH
CD96-VL
Chloramphenicol - R
Terminator tHP
GS-Linker
LAC-Promotor
Col EI ori cassette
f1 ori
SfiI (1)
SfiI (775)
 
Fig 3.4 Cloning of CD96-scFv into pAK100.  VL,  VH, and  linker. 
To verify the presence of the insert and the vector, 10 clones from the library were 
randomly selected and DNA isolation (mini preparations) was performed. The DNA 
fragments were digested with SfiI restriction enzyme. The digested fragments were 
pooled in an agarose gel. All the clones presented the recombinant insert and vector 
with expected sizes of about 800 bp and 4000 respectively (Fig 3.5).  
 
Fig 3.5 Agarose gel electrophoresis of CD96-scFv + pAK100 phagemid vector mini 
preparations. Fragment sizes are indicated in base pairs (bp).  Lane 1: 100 bp-DNA Ladder, lanes 2-
11: 10 randomly selected clones from the library which were digested with SfiI restriction enzyme. One 
representative experiment out of three is indicated.    
3.1.4 Construction of the CD96-scFv phage display library 
The CD96-scFv + pAK100 ligated mixture was precipitated with n-Butanol, and 
transformed into electrocompetent E. coli cells, strain XL1-Blue, to prepare a library 
containing scFv genes. As the hybridoma cells may carry non-functional RNA 
therefore the scFv fragments were subjected to the phage display and screened 
against CD96-positive HSB-2 cells (Fig 3.6).  
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Fig 3.6 Schematic view of scFv formation from TH-111 hybridoma cells, and selection of 
functional CD96-scFv through phage display. VH: variable domain of the antibody heavy chain, 
VL: variable domain of the antibody light chain, and scFv: single chain variable fragment. 
3.1.5 Whole cell-phage ELISA 
Polyclonal ELISA was carried out with original library, and sub-libraries of all 3 
screening rounds, to evaluate their binding specifity to the CD96 antigen and the 
enrichment of sub-libraries after screening. ELISA was performed using CD96-
positive/CD7-negative HSB-2, and CD96-negative/CD7-positive CEM cells. The 
absorbance or optical density (OD) was read at A = A (405 nm) - A (492 nm). The 
most pronounced enrichment was observed after round 2 and the highest OD was 
read at round 3 (Fig 3.7). M13 helper phages and PBS, which were used as negative 
control, presented no binding activity to CD96. CD96 (TH-111) and CD7 (TH-69) 
monoclonal antibodies which were utilized as positive control presented binding 
activity to the CD96 antigen. In the case of CEM cells only TH-69 presented binding 
activity to the CD7 antigen. Therefore bacteriophages expressing CD96-scFv 
specifically bound to the CD96 antigen, and the process of screening could remove 
the non-functional scFvs and also scFvs with weak binding activity to CD96. 
TH-111 hybridoma 
cells 
 
scFv 
scFv 
V-PCR SOE-PCR 
 
scFv gene 
phage gene III 
phage 
display 
VH 
VL 
VL 
VH 
VL 
3 x screening 
against  
CD96-positive cells  
(HSB-2 cells) protein gIII 
VH 
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Fig 3.7 Polyclonal cell-phage ELISA. A) The ELISA plate was coated with HSB-2, (first and third 
rows), and CEM cells, (second and fourth rows). B)  coating with HSB-2 cells and  coating with 
CEM cells. The cells were incubated with bacteriophages from 1: original library, 2: first round, 3: 
second round, 4: third round of screening, and also with 5: TH-111 monoclonal antibody, 6: TH-69 
monoclonal antibody, 7: helper phages, and 8: PBS. The reactions were developed using an anti-M13 
HRP-conjugated antibody. One representative experiment out of three is indicated.    
3.1.6 Sequence alignment of CD96 variable light and heavy chains 
10 single clones were picked from the last round of screening, and were sequenced. 
The sequence alignment of all CD96-scFv clones indicated expected sequence 
arrangements of variable heavy and light chains of murine IgG (Fig 3.8).  
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         SfiI 
 ~~~~~~~~~~~~~~ 
       1 GGCCCAGCCG GCCATGGCGG ACTACAAAGA CATTGTGCTG ACCCAATCTC CAGCTTCTTT 
 CCGGGTCGGC CGGTACCGCC TGATGTTTCT GTAACACGAC TGGGTTAGAG GTCGAAGAAA 
      61 GGCTGTGTCT CTAGGGCAGA GGGCCACCAT ATCCTGCAGA GCCAGTGAAA GTGTTGATAG 
 CCGACACAGA GATCCCGTCT CCCGGTGGTA TAGGACGTCT CGGTCACTTT CACAACTATC 
     121 TTATGGCAAT AGTTTTATGC ACTGGTACCA GCAGAAACCA GGACAGCCAC CCAAACTCCT 
 AATACCGTTA TCAAAATACG TGACCATGGT CGTCTTTGGT CCTGTCGGTG GGTTTGAGGA 
     181 CATCTATCGT GCATCCAATT TAGAATCTGG GATCCCTGCC AGGTTCAGTG GCAGTGGGTC 
 GTAGATAGCA CGTAGGTTAA ATCTTAGACC CTAGGGACGG TCCAAGTCAC CGTCACCCAG 
     241 TAGGACAGAC TTCACCCTCA CCATTAATCC TGTGGAGGCT GATGATGTTG CAACCTATTA 
 ATCCTGTCTG AAGTGGGAGT GGTAATTAGG ACACCTCCGA CTACTACAAC GTTGGATAAT 
     301 CTGTCAGCAA AGTAATGAGG ATCCGTACAC GTTCGGAGGG GGGACCAAGC TGGAAATAAA 
 GACAGTCGTT TCATTACTCC TAGGCATGTG CAAGCCTCCC CCCTGGTTCG ACCTTTATTT 
     361 ACGTGGTGGT GGTGGTTCTG GTGGTGGTGG TTCTGGCGGC GGCGGCTCCG GTGGTGGTGG 
 TGCACCACCA CCACCAAGAC CACCACCACC AAGACCGCCG CCGCCGAGGC CACCACCACC 
     421 ATCCGAGGTG CAGCTGAAGG AGTCTGGCCC TGGGATATTG CAGCCCTCCC AGACCCTCAG 
 TAGGCTCCAC GTCGACTTCC TCAGACCGGG ACCCTATAAC GTCGGGAGGG TCTGGGAGTC 
     481 TCTGACTTGT TCCTTCTCTG GGTTTTCACT GAACACCTCT GGTATGGGTG TAGGCTGGAT 
 AGACTGAACA AGGAAGAGAC CCAAAAGTGA CTTGTGGAGA CCATACCCAC ATCCGACCTA 
     541 TCGTCAGCCT TCAGGGAAGG GTCTGGAGTG GCTGGCACAC ATTTGGTGGG ATGATGACAA 
 AGCAGTCGGA AGTCCCTTCC CAGACCTCAC CGACCGTGTG TAAACCACCC TACTACTGTT 
     601 GCGCTATAAC CCAGCCCTGA AGAGCCGACT GACATTCTCC AAGGATACCT CCAGCAACCA 
 CGCGATATTG GGTCGGGACT TCTCGGCTGA CTGTAAGAGG TTCCTATGGA GGTCGTTGGT 
     661 GGTATTCCTC AAGATCGCCA GTGTGGACAC TGCAGATACT GCCACATACT ACTGTGTTCG 
 CCATAAGGAG TTCTAGCGGT CACACCTGTG ACGTCTATGA CGGTGTATGA TGACACAAGC 
                                                             SfiI 
                                                            ~~~~~~ 
     721 AGGGGGTAAC TCGTTTGCTT ACTGGGGCCA AGGGACTCTG GTCACTGTCT CTGCGGCCTC 
 TCCCCCATTG AGCAAACGAA TGACCCCGGT TCCCTGAGAC CAGTGACAGA GACGCCGGAG 
  SfiI 
 ~~~~~~~ 
     781 GGGGGCC 
 CCCCCGG 
Fig 3.8 Sequence alignment of CD96-scFv.  VL,  VH, and  linker. 
3.1.7 Monoclonal cell-phage ELISA 
The 10 single clones were also tested for specific binding to CD96 using ELISA. All 
clones bound specifically to HSB-2 cells. Helper phages and PBS which were used 
as negative control presented no binding activity for the CD96 antigen. Monoclonal 
CD96 (TH-111) and CD7 (TH-69) antibodies which were used as positive control 
presented binding activity to the CD96 antigen. In the case of CEM cells, only TH-69 
presented the binding activity to CD7. One clone (number 8) with high absorbance 
was selected (Fig 3.9). 
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Fig 3.9 Monoclonal cell-phage ELISA. A) The ELISA plate was coated with HSB-2 (first and third 
rows) and CEM cells (second and fourth rows). B)  coating with HSB-2 cells and  coating with CEM 
cells. The cells were incubated with bacteriophages from 1-10: 10 single clones, 11: first round of 
screening, and also with 12: TH-111 monoclonal antibody, 13: TH-69 monoclonal antibody, 14: helper 
phages, and 15: PBS. The reactions were developed using anti-M13 HRP-conjugated antibody. One 
representative experiment out of three is indicated.   
3.2 Generation and characterization of soluble CD96-scFv-IgG1-Fc  
3.2.1 Cloning of CD96-scFv into human IgG1-Fc  
For functional characterization of CD96-scFv, the selected CD96-scFv was 
genetically fused to a human IgG1-Fc part (Fig 3.10). This format of recombinant 
A 
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antibody is constructed of the scFv from mouse, and the Fc region from human 
antibody (Fig 3.11).  
pSecTag2HB-Fc-Myc-CD96 scFv
7128 bp
Murine Ig kappa-chain V-J2-C signal peptide myc epitope
Poly-HIS
IgG1-Fc
CD96-VL
CD96-VH
GS-Linker
BGH poly A
SV40 poly A
pCMV
T7 P pcDNA3.1 reverse priming site
pSV40
f1 ori
ColE1 ori
Hygromycin
Ampicillin
SfiI (1)
SfiI (6355)
 
Fig 3.10. Schematic view of scFv cloning into the pSec-IgG1-Fc vector.  VL,  VH,  linker, 
and  IgG-Fc. 
 
Fig 3.11 Construction of the scFv-IgG1-Fc mini-antibody. The scFv from the CD96 monoclonal 
mouse antibody was cloned into human IgG1-Fc part. 
3.2.2 Expression and purification of the CD96-scFv-IgG1-Fc mini-antibody 
293T cells were transient and stably transfected with the CD96-scFv-IgG1-Fc 
molecule. The supernatant was purified using protein A and IMAC affinity 
chromatography. Integrity and purity of the purified CD96-scFv-IgG1-Fc antibody was 
confirmed by SDS-PAGE and Coomassie-staining. One prominent band of about 60 
kDa was visible on reducing SDS-gel (Fig 3.12A), roughly corresponding with 
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calculated molecular weight of 56.6 kDa. Under non-reducing condition, CD96-scFv-
IgG1-Fc, demonstrated a band of about 110-120 kDa (Data not shown), indicating 
the expected dimer formation of the recombinant molecule. Western blot analysis 
further confirmed the identity of the purified protein (Fig 3.12B).  
 
Fig 3.12 Purification and analysis of the CD96-scFv-IgG1-Fc mini-antibody. The protein sizes are 
indicated in kDa. A) Coomassie blue stained SDS–PAGE gel. B) Western blot. Lanes 1 and 2: purified 
CD96-scFv-IgG1-Fc protein, lane 3: size marker, lanes 4-6: calibration with 5, 2.5 and 1.25 µg of BSA. 
Data shown are representative of five independent experiments. 
3.2.3 Binding specifity of the CD96-scFv based mini-antibody to CD96 
The binding activity and specifity of the CD96-scFv-IgG1-Fc mini-antibody was 
analyzed by flow cytometry using CD96-positive HSB-2 (Fig 3.13) and KG1a cells 
(Fig 3.14). CD96-negative CEM cells were used as negative control (Fig 3.15). 
Antigen binding was detected using Penta.His Alexa fluor conjugate. CD96-scFv-
IgG1-Fc antibody confirmed the CD96 antigen specific binding, but no binding activity 
to CEM cells was observed. Therefore CD96-scFv-IgG1-Fc could specifically bind to 
CD96.  
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Fig 3.13 Flow cytometry analysis of the recombinant CD96-scFv-IgG1-Fc mini-antibody using 
HSB-2 cells (CD96
+
 and CD7
+
). The cells were incubated with A) CD96-scFv-IgG1-Fc, B) CD7-scFv-
IgG1-Fc, and C) TH-111. The CD7 antibody was used as control. One representative experiment out 
of three is indicated.    
 
Fig 3.14 Flow cytometry analysis of the recombinant CD96-scFv-IgG1-Fc mini-antibody using 
KG1a cells (CD96
+
 and CD7
-
). The cells were incubated with A) CD96-scFv-IgG1-Fc, B) CD7-scFv-
IgG1-Fc, and C) TH-111. The CD7 antibody was used as control. One representative experiment out 
of three is indicated.    
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Fig 3.15 Flow cytometry analysis of the recombinant CD96-scFv-IgG1-Fc mini-antibody using 
CEM cells. The cells were incubated with A) CD96-scFv-IgG1-Fc, B) CD7-scFv-IgG1-Fc, C) TH-111, 
and D) TH-69. The CD7 antibody was used as control. One representative experiment out of three is 
indicated. 
3.2.4 Binding competition of the CD96-scFv based mini-antibody and the CD96 
monoclonal antibody TH-111 to CD96 
To further demonstrate that during the construction process of scFv fragment, the 
binding specificity of CD96-scFv was not altered, the binding competition of the 
CD96 recombinant mini-antibody, and the CD96 parental antibody (TH-111) to the 
CD96 antigen, was considered (Fig 3.16). High concentrations of the TH-111 
antibody inhibited the binding of the CD96 mini-antibody to CD96 (Fig 3.17B), while 
an irrelevant antibody, (TH-69), used at the same concentration, presented no 
inhibitory effect (Fig 3.17C). In conclusion, CD96-scFv retained the antigen specificity 
of the parental murine antibody.  
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Fig 3.16 Schematic view of CD96-scFv-IgG1-Fc binding competition with the TH-111 
monoclonal antibody to the CD96 antigen.  
 
Fig 3.17 Binding competition of the CD96-scFv based mini-antibody and TH-111 to CD96. HSB-
2 cells were incubated with A) CD96-scFv-IgG1-Fc, B) CD96-scFv-IgG1-Fc + TH-111, C) CD96-scFv -
IgG1-Fc + TH-69. One representative experiment out of three is indicated.  
3.2.5 Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) by the CD96-scFv 
based mini-antibody 
To indicate the cytolytic activity of the recombinant CD96-scFv-IgG1-Fc mini-
antibody, ADCC assay was performed using 51Cr labelled HSB-2 cells as target cells. 
The CD96 monoclonal antibody, TH-111, was used as control. The cells were 
incubated with antibodies and MNCs from healthy volunteers were used to trigger the 
CD96- positive cells. After 3 h incubation, the CD96-scFv-IgG1-Fc protein mediated 
low ADCC, and the CD96 mouse antibody presented very weak/no ADCC (Fig 3.18).  
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Fig 3.18 ADCC analysis of the CD96-scFv-IgG1-Fc mini-antibody and the CD96 mouse antibody 
TH-111.  CD96-scFv-IgG1-Fc and  TH-111. HSB-2 cells were used as target and MNCs as effector 
cells. E/T ratio (80:1). Data are presented as mean values +/- SEM from five independent 
experiments. 
3.3 Generation of CD96-scFv with improved binding affinity to CD96  
3.3.1 Construction of a mutated CD96-scFv library  
To optimize the cytolytic potential of the CD96-directed mini-antibody, the binding 
affinity of CD96-scFv to CD96 was enhanced. The coding sequence of the CD96-
specific scFv fragment was amplified, using error-prone PCR, thereby introducing 
random mutations with low frequency (Fig 3.19). Lower PCR mutation frequencies 
could be achieved by using higher DNA template concentrations to limit the number 
of target duplications. In this test an initial target amount of 1000 ng is used to 
achieve low mutation frequencies of 0-4.5 mutations/kb. The amplified product was 
used to generate a “diversified” phage display library, and a library with 1 x 106 
independent clones was constructed.  
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 Fig 3.19 Agarose gel electrophoresis of the mutagenesis-PCR of CD96-scFv. Fragment sizes 
are indicated in base pairs (bp).  Lane 1: 100 bp-DNA Ladder, lane 2: mutated-scFv, and lane 3: H2O 
as negative control. One representative experiment out of three is indicated. 
3.3.2 Generation, expression and purification of the CD96-ECD protein 
For the panning of “diversified” phage display library under stringent washing-
selection conditions and remove the wild type CD96-scFv from the library, CD96-
ECD was generated. Total RNA was isolated from CD96-positive HSB-2 cells, and 
the CD96-ECD was amplified by OneStep RT-PCR. CD96-ECD was cloned into a 
human IgG-Fc portion to facilitate of protein purification (Fig 3.20). 293T cells were 
transient and stably transfected with CD96-ECD-IgG1-Fc. The integrity and purity of 
the purified protein was confirmed by SDS-PAGE and Coomassie staining. One 
prominent band of about 200 kDa was visible on Coomassie-stained reducing SDS-
gel (Fig 3.21A). Western blot analysis further confirmed the identity of the purified 
protein (Fig 3.21B).  
3. RESULTS   
 71 
pSecTag2HB-Fc-Myc-CD96 ECD
7779 bp
CD96-ECD
huIgG1-Fc
myc epitope
Poly-HIS
BGH poly A
SV40 poly A
pCMV T7 P
pcDNA3.1 reverse priming site
pSV40
f1 ori
ColE1 ori
Hygromycin
Ampicillin
EcoRI (3646)
NcoI (9)
NcoI (3246)
NcoI (3755)
NcoI (7495)
 
Fig 3.20 Schematic view of CD96-ECD cloning into the pSec-IgG1-Fc vector.  CD96-ECD and  
IgG1-Fc.  
 
Fig 3.21 Purification and analysis of the CD96-ECD-IgG1-Fc protein. The protein sizes are 
indicated in kDa. A) Coomassie blue stained SDS–PAGE gel. B) Western blot. Lanes 1 and 2: purified 
CD96-ECD-IgG1-Fc protein, lane 3: size marker and lanes 4-6: calibration with 1.25, 0.65 and 0.31 µg 
of BSA. Data shown are representative of four independent experiments. 
3.3.3 Binding specifity of the CD96 antibody to CD96-ECD 
To test proper native protein folding a capture ELISA assay was established. The 
ELISA plate was coated with the CD96-ECD protein. The plate was incubated with 
the TH-111 or TH-69 irrelevant antibody. TH-111 bound to CD96-ECD while TH-69 
presented no binding activity (Fig 3.22). Therefore recombinant CD96-ECD protein is 
correctly folded. 
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Fig 3.22 Binding specifity of the CD96 antibody and the CD96-ECD. ELISA was performed with   
 TH-111 and  TH-69 antibodies. (*): significant difference in binding activity. One representative 
experiment out of three is displayed. 
3.3.4 Selection of the CD96-scFv mutant library with enhanced binding affinity  
The “diversified” phage display library was screened in five rounds using the 
recombinantly expressed CD96-ECD as antigen under stringent washing conditions 
to eliminate wild type CD96-scFv. 30 randomly selected clones from the last 
screening of the “diversified” phage display library were sequenced and compared to 
sequences obtained from the original library.  
3.3.5 Sequence analysis of variable regions of mutated CD96-scFv  
Sequence analysis of clones obtained from the original library revealed that 0-4 
mutations were introduced in each clone that resulted in amino acid exchanges and 
that mutation sites were randomly distributed in both VH and VL genes (Fig 3.23).  
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Fig 3.23 Sequence alignment of VL and VH domains of mutated CD96-scFv from the original 
library. VL-0: variable light chain of clones from the original library. VH-0: variable heavy chain of 
clones from the original library. The CDRs are defined according the Kabat database.  CDR1,  
CDR2,  CDR3, and  mutation position. The clones with same mutations were displayed only once.  
 
 
 
Fig 3.24 Sequence alignment of the VL and VH domains of mutated CD96-scFv from the fifth 
sub-library. VL-5: variable light chain of clones from the fifth sub-library. VH-5: variable heavy chain 
of clones from the fifth sub-library. The CDRs are defined according the Kabat database.  CDR1,  
CDR2,  CDR3, and  mutation position. The clones with same mutations were displayed only once. 
After five round of screening, 29 of 30 clones showed amino acid exchanges (Fig 
3.24), while only one wild type clone was picked. This data indicated that wild type 
scFvs were successfully eliminated during the selection procedure. Most amino acid 
exchanges were found in VH, in the CDRH1 domain while only one clone with a 
mutation in the VL domain was found. The most striking mutation was detected at 
amino acid position H32 (Ser
H32), which resulted in a serine to phenylalanine 
substitution (SerH32  PheH32) (S32F). A missense mutation resulting in a serine to 
proline exchange (SerH32  ProH32) (S32P) was the second most abundant mutation 
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at the same amino acid position. In 5 clones, an amino acid exchange in the CDRH3 
domain was observed, resulting in an asparagine to aspartic acid substitution                         
(AsnH97  AspH97) (N97D) (Fig 3.24).  
3.3.6 Calculated homology model of wild type CD96-scFv 
To obtain first indications whether the identified positions in the VH domain may 
directly contribute to CD96 binding, a homology model of wild type CD96-scFv was 
calculated (Fig 3.25). This model would predict that two most common positions 
found to be altered in CDRH1 and CDRH3 are surface exposed, and therefore may 
directly contribute to CD96 binding.  Clone 1, (S32F or mut1), carrying mutation 
identically found in 19 other clones including the most abundantly detected CDRH1 
mutation was chosen for further analysis. 
 
Fig 3.25 Calculated homology model of wild type CD96-scFv. A) A homology model of wild type 
CD96-scFv was calculated using the Rosetta server/algorithm (Sircar et al., 2009) and displayed as a 
surface model using the Accelrys DS Viewer software. B) Top view of the model displayed in (A). The 
6 loops defining the CDRs were assigned according to the Kabat numbering scheme.  Heavy chain 
CDRs,  light chain CDRs,  heavy chain frameworks,  light chain frameworks, and  positions 
found mutated after screening; mut1 = S32F and  mut2 = N97D.    
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3.4 Generation and characterization of monovalent CD96-scFv 
3.4.1 Expression and purification of monovalent CD96-scFv  
To analyze whether the detected amino acid exchanges resulted in altered/stronger 
antigen binding, monovalent CD96-scFv, the wild type (CD96-wt-scFv) and the 
mutated variant (CD96-S32F-scFv) were expressed in E. coli cells. Coomassie-
stained gel of the purified CD96-scFvs presented the size of proteins corresponded 
with the expected molecular weights of about 30 kDa (Fig 3.26A). Western blot 
analysis confirmed the identity of the purified scFvs (Fig 3.26B). 
 
Fig 3.26 Purification and analysis of monovalent CD96-scFv. The protein sizes are indicated in 
kDa. A) Coomassie blue stained SDS-PAGE. B) Western blot. Lane 1: CD96-S32F-scFv, lane 2: 
CD96-wt-scFv, lane 3: size marker and lanes 4-9: calibration with 0.08, 0.15, 0.3, 0.65, 1.25 and 2.5 
µg of BSA. Data shown are representative of three independent experiments. 
3.4.2 Binding specifity of monovalent CD96-scFv to CD96 
The binding activity and specifity of CD96-scFv was analyzed by flow cytometry 
using CD96-positive HSB-2 cells, and CD96-negative CEM cells as negative control 
(Fig 3.27). The antigen binding was detected using Penta.His Alexa fluor conjugate. 
CD96-scFv wild type and mutated variant confirmed the CD96 antigen specific 
binding and no binding activity to CEM cells was presented. Therefore the wild type 
and the mutated variant of CD96-scFv could bind specifically to CD96 (Fig 3.27).  
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Fig 3.27 Flow cytometry analysis of monovalent CD96-scFv using HSB-2 and CEM cells. HSB-2 
cells were incubated with A) wild type CD96-scFv, C) mutated CD96-scFv and CEM cells were 
incubated with B) wild type CD96-scFv, D) mutated CD96-scFv. One representative experiment out of 
three is indicated.    
3.4.3 Affinity comparison of the monovalent CD96-scFv wild type and the 
mutated variant 
To indicate the comparative binding affinity of the CD96-scFv wild type and the 
mutated variant to CD96, the HSB-2 cells were incubated with serial dilutions of 
CD96-wt-scFv and CD96-S32F-scFv and dose-dependent binding of these two 
antibodies was analyzed. The CD96-S32F-scFv demonstrated about 3-fold 
enhanced binding (EC50 = 3.3 µg/ml; 95% confidence interval = 3.0-3.7) compared to 
CD96-wt-scFvs (EC50 = 8.9 µg/ml; 95% confidence interval = 8.0-9.8) (Fig 3.28). 
Therefore mutation of CD96-scFv improved the binding affinity of this antibody to the 
CD96 antigen.  
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Fig 3.28 Dose dependent binding analysis of CD96-scFvs to CD96 by flow cytometry using 
HSB-2 cells.  CD96-wt-scFv,  CD96-S32F-scFv. (*): significant differences in binding at the 
indicated dose level. Data are presented as mean values +/- SEM from three independent 
experiments. 
3.5 Construction and characterization of bivalent CD96-scFv-IgG1-Fc mini-
antibodies  
3.5.1 Cloning of CD96-scFv into the engineered IgG1-Fc region (IgG1-Fc-eng) 
To increase the ADCC effect of the CD96-scFv-IgG1-Fc antibody, the variable genes 
of this antibody were mutated to enhance binding affinity of CD96-scFv to CD96 (Fig 
3.30). The second approach to increase the ADCC effect of this recombinant 
antibody was Fc-engineering which enhanced FcγR binding affinity, leading to 
improved FcγR-dependent effector cell function, ADCC (Fig 3.29). The wild type and 
mutated variant of CD96-scFv were cloned into IgG1-Fc-eng which has three 
mutation in CH2 and was approved for improved ADCC (Lazar et al., 2006; Repp et 
al., 2010), resulting CD96-wt-scFv-IgG1-Fc-eng and CD96-S32F-scFv-IgG1-Fc-eng 
(Fig 3.30).  
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Fig 3.29 Schematic view of different formats of the CD96-scFv based mini-antibody. The scFv-
wild type and the mutated variant of CD96-scFv were cloned into IgG1-Fc-eng. 
CD96-mut-scFv-IgG1-Fc-eng
scFv
V-regions-error-prone PCR
Fc-Mutation
Fc
 
Fig 3.30 Optimizing of ADCC activity of the CD96-scFv-IgG1-Fc antibody. To increase ADCC 
activity 1) CD96 variable genes were subjected to error-prone PCR. 2) CD96-scFv was cloned into 
engineered IgG1-Fc with three mutations in CH2, (S239D/I332E/A330L). 
3.5.2 Expression and purification of optimized CD96 mini-antibodies  
293T cells were transient and stably transfected with CD96-wt-scFv-IgG1-Fc-eng 
and CD96-S32F-scFv-IgG1-Fc-eng mini-antibodies. Coomassie-stained gel of both 
purified antibodies presented one prominent band of about 60 kDa roughly 
corresponding with the calculated molecular weight of 56.6 kDa (Fig 3.31A). Western 
blot analysis confirmed the identity of the purified scFvs (Fig 3.31B).  
Fc-eng 
Fc-eng scFv-mut 
scFv-wt 
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Fig 3.31 Purification and analysis of CD96-scFv-IgG1-Fc. The protein sizes are indicated in kDa. 
A) Coomassie blue stained SDS-PAGE gel. B) Western blot. Lane 1: CD96-S32F-scFv-IgG1-Fc-eng, 
lane 2: CD96-wt-scFv-IgG1-Fc-eng, lane 3: size marker and lanes 4-9: calibration with 0.15, 0.31, 
0.65, 1.25, 2.5 and 5 µg of BSA. Data shown are representative of five independent experiments. 
3.5.3 Binding specifity of the mutated CD96-scFv based mini-antibody (CD96-
S32F-scFv-IgG1-Fc) to CD96 
The binding activity and specifity of the CD96-scFv based mini-antibody (CD96-
S32F-scFv-IgG1-Fc) was analyzed by flow cytometry using CD96-positive HSB-2 
cells (Fig 3.32A), and CD96-negative CEM cells (Fig 3.32B) as negative control. 
Antigen binding was detected using Penta.His Alexa fluor conjugate. The CD96-
scFv-IgG1-Fc antibody confirmed the CD96 antigen specific binding, and no binding 
activity to CEM cells was observed. Therefore CD96-S32F-scFv-IgG1-Fc could 
specifically bind to CD96.  
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Fig 3.32 Flow cytometry analysis of the recombinant mutated CD96-scFv (CD96-S32F) based 
mini antibody. A) The HSB-2 cells were incubated with CD96-S32F-scFv-IgG1-Fc and B) The CEM 
cells were incubated with CD96-S32F-scFv-IgG1-Fc. One representative experiment out of three is 
indicated.    
3.5.4 Binding competition of the mutated CD96-scFv based mini-antibody 
(CD96-S32F-scFv) and the CD96 monoclonal antibody TH-111 to CD96 
To further demonstrate, that during the construction process of optimized-CD96- 
scFv, the binding specificity of scFv was not altered, the binding competition of 
CD96-S32F-scFv-IgG1-Fc and the CD96 parental antibody TH-111 to the CD96 
antigen was considered. High concentration of the TH-111 antibody inhibited the 
binding of CD96-S32F-scFv-IgG1-Fc to CD96 (Fig 3.33B), while the TH-69 irrelevant 
antibody utilized at the same concentration displayed no inhibitory effect (Fig 3.33C).  
 
Fig 3.33 Binding competition of the mutated CD96-scFv (CD96-S32F) based mini antibody and 
TH-111 to CD96. HSB-2 cells were incubated with A) CD96-S32F-scFv-IgG1-Fc, B) CD96-S32F-
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scFv-IgG1-Fc + TH-111, C) CD96-S32F-scFv-IgG1-Fc + TH-69. One representative experiment out of 
three is indicated.    
3.5.5 Binding comparison of wild type and mutated CD96-scFv-IgG1-Fc mini-
antibodies to CD96 
To evaluate dose dependent binding of bivalent mini-antibody constructs, wild type 
and mutated CD96-scFv-IgG1-Fc were compared. HSB-2 cells were incubated with a 
serial dilution of these antibodies and were analyzed on a flow cytometer. A 4-fold 
improvement in binding of mutated CD96-scFv-based mini-antibody to CD96 was 
detected compared to wild type variant (Fig 3.34). CD96-S32F-scFv-IgG1-Fc-eng 
and CD96-wt-scFv-IgG1-Fc-eng demonstrated EC50-values of 19.5 µg/ml (95% CI = 
15.7-24.3) and 79.9 µg/ml (95% CI= 32.8-194.7) respectively, indicating that no 
avidity effect was observed.  
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Fig 3.34 Dose dependent binding analysis of mini-antibodies by flow cytometry using HSB-2 
cells.  CD96-wt-scFv-IgG1-Fc,  CD96-S32F-scFv-IgG1-Fc. (*): significant differences in binding at 
the indicated dose level. Data are presented as mean values +/- SEM from five independent 
experiments. 
3.5.6 Comparison of ADCC activity of CD96 antibodies 
The cytolytic properties of recombinant CD96 mini-antibodies were investigated by 
chromium release cytotoxicity assay with CD96-positive HSB-2 cells and isolated 
MNCs. The double-engineered CD96 mini-antibody (affinity-maturated scFv and 
optimized Fc part, CD96-S32F-scFv-IgG1-Fc-eng) proved to be significantly better in 
mediating tumor cell lysis in comparison to its non-affinity maturated counterpart at 
saturating concentrations, demonstrating that the gain in affinity translated in 
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improved ADCC potency. CD96-wt-scFv-IgG1-Fc-eng also performed significantly 
higher ADCC compared to CD96-wt-scFv-IgG1-Fc. Therefore Fc-engineering alone, 
leading to enhanced FcγR binding affinity, already improved cytolytic ADCC. The TH-
111 monoclonal antibody showed only extremely weak/no ADCC. Briefly, the three 
variants of the CD96-specific mini-antibody demonstrated cytolytic activity to CD96-
positive cells with CD96-S32F-scFv-IgG1-Fc-eng > CD96-wt-scFv-IgG1-Fc-eng > 
CD96-wt-scFv-IgG1-Fc > TH-111 (Fig 3.35). 
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Fig 3.35 Comparison of ADCC activity of CD96 antibodies. ADCC experiments with HSB-2 cells 
were performed using mononuclear cells as effector cells.  CD96-S32F-scFv-IgG1-Fc-eng,  CD96-
wt-scFv-IgG1-Fc-eng,  CD96-wt-scFv-IgG1-Fc, and  TH-111. (*): significant differences in ADCC 
activity. E/T ratio (80:1). Antibody concentration 200 µg/ml. Data are presented as mean values +/- 
SEM from five independent experiments. 
3.5.7 Comparison of dose-dependent ADCC activity of CD96 antibodies  
The CD96-positive HSB-2 (Fig 3.36) and KG1a cells (Fig 3.37) were used to 
compare dose-dependent ADCC activity of CD96 mini-antibodies. The CD96 mini-
antibody with mutated scFv, and also engineered Fc (CD96-S32F-scFv-IgG1-Fc-
eng), presented better ADCC compared to the antibody format with wild type scFv 
but the engineered-Fc part (CD96-wt-scFv-IgG1-Fc-eng). 
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Fig 3.36 Dose dependent killing of Fc-engineered CD96-mini-antibodies with HSB-2 cells.          
 CD96-wt-scFv-IgG1-Fc-eng,  CD96-S32F-scFv-IgG1-Fc-eng,  CD20-scFv-IgG1-Fc-eng, and    
 TH-111. (*): significant differences in ADCC activity. E/T ratio (80:1). Data are presented as mean 
values +/- SEM from five independent experiments. 
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Fig 3.37 Dose dependent killing of Fc-engineered CD96-mini-antibodies with KG1a cells.          
 CD96-wt-scFv-IgG1-Fc-eng,  CD96-S32F-scFv-IgG1-Fc-eng,  CD20-scFv-IgG1-Fc-eng, and    
 TH-111. (*): significant differences in ADCC activity. E/T ratio (80:1). Data are presented as mean 
values +/- SEM from four independent experiments. 
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4. DISCUSSION 
4.1 CD96 mini-antibody 
In the present study, the functional variable regions of a CD96 monoclonal antibody 
were isolated and a CD96-scFv molecule was generated. To study the effector 
mechanisms of CD96-scFv, this molecule was cloned into an IgG1-Fc portion and a 
chimeric CD96-scFv-IgG1-Fc mini-antibody (CD96-scFv-IgG1-Fc) was generated. 
This mini-antibody bound to CD96 antigen specifically. In addition, the CD96-scFv-
based mini-antibody binding to CD96 antigen was inhibited, in the presence of 
excess monoclonal CD96 antibody. Accordingly the CD96-scFv-IgG1-Fc mini-
antibody retained the binding specifity of parental monoclonal antibody. The CD96-
scFv-based mini-antibody mediated ADCC only weakly. Consequently in vitro affinity 
maturation and Fc engineering of this antibody showed enhanced ADCC activity. The 
engineered CD96-scFv mini-antibodies were tested for their ability to elicit ADCC in 
vitro, against two tumor cell lines. The molecule with engineered-Fc and mutated-
scFv showed the most effective ADCC. These results demonstrated that, both 
antigen binding affinity and Fc receptor binding, regulate ADCC activity and 
obviously persuade the efficacy of ADCC.  
 
4.2 ScFv-Fc characteristics 
The CD96 monoclonal mouse antibody, TH-111, was previously generated in our 
lab. For clinical use of mouse antibodies in humans, the immunogenicity of these 
antibodies has to be reduced. Furthermore, mouse antibodies are not efficient in 
recruiting the human immune system and effector functions. Therefore, the CD96 
monoclonal mouse antibody was replaced by a recombinant antibody. Recombinant 
single chain variable fragment (scFvs) is one of the most commonly used formats of 
recombinant antibodies (Peipp et al., 2004). ScFv and scFv-based antibodies are 
promising therapeutic and diagnostic alternative to monoclonal antibodies in the 
treatment of cancer, autoimmune, inflammatory and chronic viral diseases (Weisser 
and Hall, 2009). The production and purification of these molecules is uncomplicated. 
They can be expressed in large scales in both prokaryotic and eukaryotic expression 
systems. The scFv-based mini-antibody displays functional characteristics similar to 
that of a complete antibody and can mediate effector mechanisms of whole IgG1 
molecule. The scFv-Fc fusion protein has a lower molecular weight in comparison to 
the whole IgG1 molecule. The molecular weight is reduced by roughly one third, 
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probably shows improved tumor penetrating characteristics. The use of recombinant 
antibody technology to design scFv-based antibody derivatives may allow further 
optimization of these therapeutically interesting molecules (Winter and Milstein, 
1991). Fc-engineering strategies such as fucose removal and amino acid 
substitutions, which improve effector mechanisms of complete IgG1 molecules, could 
enhance the effector mechanisms of mini-antibodies.  
In the current study a CD96-scFv-based mini-antibody, which represents one 
promising new molecule format of therapeutic antibodies, was generated. 
4.3 Improvement of ADCC by engineering of the CD96-scFv-based mini-
antibody  
It has been proposed that tumor cells show resistance to therapeutic antibodies, 
through different mechanisms. This reduces the efficacy of antibodies for tumor cells 
lysis (Smith, 2003). To overcome this resistance, the effector functions of therapeutic 
antibodies can be optimized. Several strategies are known to increase the antitumor 
efficacy of therapeutic antibodies by enhancing ADCC activity (Smith, 2003; Weiner, 
2005; Weiner and Carter, 2005). Consequently in vitro affinity maturation of antibody 
V-genes to improve binding affinity, to target antigens and Fc engineering, to 
enhance binding affinity to Fc receptors on effector cells have been described, as 
technologies suitable for enhancing ADCC. In addition to antibody binding affinity, 
the density of antigen on the tumor cell surface is also an important factor for ADCC 
efficacy (Tang et al., 2007). A previous study showed that ADCC mediated by 
trastuzumab, an antibody directed against HER2/neu, is associated with the antigen 
expression levels  (Mimura et al., 2005). But high affinity antibodies can mediate 
efficient ADCC even with cells that express target antigen in relatively low levels.  
In the present study, the engineered CD96-scFv-based mini-antibody performed 
ADCC effectively, even with cells that express CD96 in quite low levels.  
4.3.1 Random mutagenesis of CD96 V-genes  
Antibodies which are generated in a primary immune response usually have 
moderate binding affinities. These affinities are maturated/enhanced in a later 
response, which occurs in antibody V-genes of B cells in germinal centers. This 
process is known as somatic hypermutation. Hypermutation process introduces point 
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mutations into the variable regions of the heavy and light chain genes, giving rise to 
mutant B cell receptors on the surface of B cells (Kocks and Rajewsky, 1989). Some 
of these mutant immunoglobulin molecules can bind to antigen, better than the 
original B cell receptors. B cells, which express these mutant immunoglobulin 
molecules, are preferentially selected to mature into antibody secreting cells. This in 
vivo process can be mimicked in vitro by random mutation of antibody V-genes 
(Chowdhury and Pastan, 1999). The selection of mutated molecules with high 
binding affinity can be performed under stringent selection conditions, through phage 
display. The most important advantage of random mutagenesis is that, a large 
number of mutant clones can be generated. A main disadvantage is that, only a few 
of mutant clones will maintain their antigen binding potential (Miyazaki et al., 1999). 
In the current study, the entire CD96-scFv was subjected to a random mutagenesis 
with low mutation rate, through an error-prone PCR. Mutation with high frequency is 
likely to yield a large number of non-functional clones (Daugherty et al., 2000), 
therefore the condition for mutation with a low frequency was used. The final phage 
display library was 1 x 106 in size, which had scFvs with different mutations. To 
select strong binding scFvs and remove wild type scFvs, phage clones were selected 
by stringent selections through binding to purified CD96-ECD protein and sequential 
washing process. These washing conditions were optimized for complete removal of 
wild type scFv-expressing bacteriophages. 30 randomly selected phage clones from 
the last screening round of the mutated phage display library were sequenced, and 
compared to sequences obtained from the original library. The clones from the 
original library had 0-4 mutations in variable genes that resulted in amino acid 
exchanges and the mutation positions were randomly distributed in both VH and VL 
genes. After five rounds of screening, 29 of 30 clones had amino acid exchanges, 
and only one wild type clone was observed. Therefore all wild type scFvs were 
successfully removed through the selection procedure.   
Most amino acid exchanges were in CDRH1 at amino acid position H32 (Ser
H32), a 
serine to phenylalanine substitution. Only one clone with a mutation in the VL 
domain, in CDRL3 was found. These data may indicate that mutations in the VL 
region resulted in scFv variants with diminished or similar binding characteristics in 
the range of the wild type scFv and were therefore eliminated during the stringent 
screening process. In 5 clones, an amino acid exchange in the CDRH3 region was 
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observed, resulting in an asparagine to aspartic acid substitution at position H97 
(AsnH97).  
It seems likely, that exchanges in positions H32 and H97 are important for antibody 
binding to CD96 antigen. Some previous studies demonstrated that even a single 
amino acid substitution can dramatically change antigen binding affinity (Sharon, 
1990; Xiang et al., 1993). To confirm the importance of these amino acid exchanges, 
a homology model of wild type CD96-scFv was calculated. This model demonstrated 
that the two most common positions, which are altered in CDRH1 and CDRH3, are 
surface exposed and consequently may represent direct interaction sites of antibody 
and antigen.  
In different previous studies, mutations were subjected only in CDRs using different 
mutagenesis methods. These studies demonstrated the importance of several 
residues in the CDR loop, which are responsible for improved binding affinity 
(Webster et al., 1994; Yang et al., 1995; Yelton et al., 1995; Low et al., 1996; 
Aburatani et al., 2002; Dong et al., 2003; Yuan et al., 2006; Kobayashi et al., 2010). 
Affinity maturation of the human anti-HER2/neu (c-erbB-2) scFv ,C6.5, produced by 
site-directed mutagenesis in CDRH3, showed a 320-fold higher affinity to the antigen  
in comparison to the wild type antibody (Adams et al., 1998). Adams and his 
colleagues reported the first examination of the affinity effects on tumor targeting by 
antibody based molecules that bind to the same antigen. They showed that, the 
degree and specificity of tumor localization in mice, were increased significantly with 
increasing antigen binding affinity (Adams et al., 1998). Yoon and his collegeaues 
generated, AKA, an anti-TAG-72 humanized antibody. The tumor-associated 
glycoprotein, (TAG)-72, is expressed in the majority of human adenocarcinomas. 
This humanized antibody showed an approximate 2-fold lower affinity in comparison 
to the original murine monoclonal antibody. The affinity of this antibody was 
increased by random mutagenesis of the CDRH3 domain. The highest affinity 
variant, 3E8, showed approximate a 22-fold higher affinity and 2-fold improved tumor 
targeting in comparison to AKA. The antibody with improved affinity showed a 1.7-
fold improvement in tumor-specific growth delay and 50% survival rate in comparison 
to the control in athymic mice bearing human colon adenocarcinoma xenografts 
(Yoon et al., 2006). 
In the current study, randomal mutations were subjected to V-genes completely.  
After strigent washing processes, the clones with mutations in CDRs remained. It 
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confirmed the importance of the CDRs in the antigen binding affinity. The flow 
cytometry experiments with the most abundantly detected mutant, S32F (SerH32 to 
PheH32), showed an approximate 3-4 fold improved binding to CD96. This 
improvement in binding affinity of the S32F mutant to CD96 was due to a substitution 
of a polar amino acid (Ser) to a non-polar amino acid (Phe) in V-regions. This 
substitution demonstrated that, a hydrophilic surface was replaced with a 
hydrophobic surface. It was previously explained that hydrophobic interactions are 
the major driving force for protein-protein binding interactions (Wang et al., 2009). A 
previous study also showed that increasing buried hydrophobic surface and reducing 
buried hydrophilic surface is an efficient approach to improve the protein-protein 
binding affinity (Sammond et al., 2007). Sundberg and his colleagues reported a 
strong relation between a reduction in buried nonpolar accessible surface and an 
increase of the free binding energy which induces instability of protein-protein binding 
(Sundberg et al., 2000). Therefore an enhancement in nonpolar surface area 
reduces the free energy of binding and improves protein-protein binding stability. 
4.3.2 Fc-engineering  
ADCC of IgG antibodies are mediated by engagement of the Fc region of the 
antibody with FcγRs of immune effector cells (Lazar et al., 2006). In vivo studies with 
some clinically approved antibodies in γ-chain knock-out mice, which leak activating 
FcγRs expression, showed no therapeutic activity in such animal models (Clynes et 
al., 2000). In addition, some clinical studies showed a relation between FcγRs 
polymorphisms and enhanced FcγR-dependent effector functions, such as ADCC. 
This relation was particularly defined in cancer patients homozygous for the FcγRIIIa-
V158 allele treated with therapeutic antibodies such as rituximab (Weng and Levy, 
2003) and trastuzumab (Musolino et al., 2008). FcγRIIIa, (CD16a), is a main ADCC 
triggering receptor in NK cells and FcγRIIIa-V158 allele is the high affinity allotype of 
FcγRIIIa for IgG1-Fc portion. The relation between this polymorphism and the clinical 
responses in some other diseases, such as Crohn’s disease patients treated with 
anti-TNF-α infliximab and pregnant women with fetal hemolytic disease treated with 
anti-RhD, was also confirmed (Louis et al., 2004; Miescher et al., 2004). Therefore 
Fc-mediated ADCC enhancement technology seems to play an important role in the 
development of therapeutic antibodies (Natsume et al., 2009). 
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ADCC can be improved by engineering the coding of amino acid sequences of the 
constant regions of antibodies (Shields et al., 2001; Aburatani et al., 2002; Okazaki 
et al., 2004; Lazar et al., 2006) or by altering the glycosylation profile of antibodies 
(Shields et al., 2002; Okazaki et al., 2004; Peipp et al., 2008b), which improves 
binding affinity to FcγRIIIa in NK cells.  
Different research groups produced optimized-Fc variants with enhanced binding 
affinity to FcγRIIIa. The Xencor group, generated Fc variants with strong FcγRIIIa 
binding and enhanced cytotoxic efficacy in cynomolgus monkeys, using a 
computational design algorithm (Lazar et al., 2006). The Genentech group, 
developed Fc variants, including up to three mutations which showed enhanced 
ADCC, using a comprehensive alanine scanning method (Shields et al., 2001). The 
MacroGenics group, produced Fc mutants with enhanced ADCC, using a yeast 
display system (Stavenhagen et al., 2007; Stavenhagen et al., 2008).   
In the present study a protein-engineered IgG1-Fc variant was utilized to improve NK 
cell mediated killing of scFv-based mini-antibodies. This protein-engineered IgG1-Fc 
variant, with three mutations (S239D/I332E/A330L) in CH2 of the Fc region, was 
previously reported as a variant with high binding affinity to FcγRIIIa in NK cells and 
improved ADCC performance (Lazar et al., 2006; Repp et al., 2010). The CD96-
scFv-based mini-antibody with protein-engineered IgG1-Fc variant, performed a 
higher ADCC compared to mini-antibody with a non-engineered IgG1-Fc variant, but 
the CD96-scFv mini-antibody, with double engineering, optimized-Fc and mutated- 
scFv, showed the most effective ADCC. In conclusion, the ADCC activity of the Fc-
engineered mini-antibody was further improved when the affinity maturated scFv was 
utilized. This confirmed other studies which demonstrated that ADCC activity 
correlates with antibody binding affinity (Tang et al., 2007). 
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5. OUTLOOK 
5.1 CD96 mini-antibody in clinical trials  
CD96 antibody could be an excellent antibody-based therapeutic agent against AML 
stem cells and AML blasts. As CD96 is expressed on normal hematopoietic stem 
cells in a very low level, the CD96 antibody could be used for ex vivo purging or 
FACS selection of AML stem cells from autologous stem cell preparations. This 
antibody could be used also for in vivo targeting of AML stem cells and blasts in AML 
patients (Hosen et al., 2007).  
5.2 CD96 mini-antibody ADCC activity in vivo 
A further analysis of a large number of AML samples will be required to fully clarify 
the ADCC activity of CD96 mini-antibodies with freshly prepared CD96+ AML cells 
from AML patients. Antibody activity in vitro can not predict activity in vivo. In 
addition, the response to antibody in different patients is depended to various factors 
such as antigen density on target cells, levels of circulating Ig and the function of the 
effector cells. Some antibodies perform effective ADCC in vitro but are not efficient in 
clinical trials. Rituximab performs ADCC and CDC in vitro, while the main 
determinants of its clinical efficacy have not been defined (Eccles, 2000). The 
xenotransplantation experiments could reveal in vivo anti-tumor effect of CD96 mini-
antibodies. 
5.3 CD96 expression in other hematopoietic cells or nonhematopoietic tissues 
CD96 is not expressed in RBCs, monocytes, granulocytes, and B cells (Wang et al., 
1992; Gramatzki et al., 1998). CD96 is only weakly expressed in peripheral T cells, 
and this expression increases in activated T cells (Wang et al., 1992). This antigen 
was found on a major subset of T-cell acute lymphoblastic leukemia (T-ALL) 
(Gramatzki et al., 1998; Burger et al., 1999). CD96 has been reported to be 
expressed in peripheral NK cells at a expression level even lower than peripheral T 
cells (Wang et al., 1992). CD96 expressed on NK cells has been indicated as a 
ligand for CD155 (polio virus receptor), and mediates adhesion of NK cells to tumor 
cells, thereby it modulates the effector function of NK cells (Fuchs et al., 2004). For in 
vivo use of the CD96 antibody, the expression of CD96 in T and NK cells has to be 
considered. 
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CD96 is expressed on AML-LSCs (Hosen et al., 2007) and on the majority of blasts 
in about 30% of patients (Gramatzki et al., 1998). To date only a few potential target 
antigens for AML stem cells have been determined. These include CD33 (Bernstein 
et al., 1992), CD123 (Sievers et al., 1999; Jordan et al., 2000), CD44 (Jin et al., 
2006) and CD47 (Majeti et al., 2009). Most of these target antigens have some 
disadvantages, such as expression on normal hematopoietic stem cells.  But CD96 is 
expressed in very low levels in normal hematopoietic stem cell. For clinical uses of 
CD96 mini-antibodies, a further analysis such as ex vivo purging, colony assays and 
AML stem cells transplantation in mice will be required to completely demonstrate 
that these antibodies do not impair normal hematopoietic cells.  
In nonhematopoietic tissues, CD96 is expressed in the convoluted tubular epithelium 
of the kidney, in the mucosal epithelium of the small intestine, in the mucosal 
epithelium and the vascular endothelium of the large intestine (Gramatzki et al., 
1998). Expression of CD96 on the surface of vascular endothelium maybe 
problematic for clinical use, potentially leading to vascular damage, causing capillary 
leak syndrome. The expression on mucosal epithelium maybe less problematic 
because of the inaccessibility of antibodies to the luminal side of the intestine. In 
order to determine the potential disadvantages of CD96 mini-antibodies in clinical 
uses and to show the expression level of CD96 in other potential targets, 
immunohistochemical staining of different tissues is essential.  
In addition, human CD96 is expressed in two splice variants, variant 1 and variant 2. 
Variant 2 predominates in all the CD96+ cells and tissues, but some AML tumor 
samples express variant 1 of CD96 (Meyer et al., 2009). The variant of CD96+ AML 
stem cells should also be determined. If the AML stem cells express variant 1, an 
antibody specific against variant 1 can be produced and used for efficient targeting of 
AML stem cells.  
5.4 Humanized antibody 
The chimeric antibodies possess a fully human Fc portion. Therefore, these 
antibodies are significantly less immunogenic in humans and are able to interact with 
human effector cells and the complement cascade. The use of chimeric antibodies 
significantly reduced the HAMA responses of mouse antibodies but did not eliminate 
them completely. Therefore the probability of HAMA responses, shown in multiple 
clinical trials, must be considered (Kuus-Reichel et al., 1994; Pimm, 1994). In 
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addition, for certain targets, fully humanized antibodies are necessary to achieve 
maximal efficacy.  
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CONCLUSION 
CD96 was reported as an AML stem cell marker. It was also detected on the majority 
of leukemic blasts in about 30% of AML patients. Therefore, CD96 could be an 
efficient antigen to target AML stem cells and blasts. The CD96 mouse monoclonal 
antibody, (TH-111), was previously generated in our lab. To reduce the 
disadvantages of mouse antibody, the variable regions of this antibody were isolated 
and a CD96-scFv was generated by phage display. For functional analysis of this 
antibody, CD96-scFv was cloned into a human Fc-IgG1 portion. The CD96-scFv-
based mini-antibody (CD96-scFv-IgG1-Fc) mediated ADCC only weakly. Two 
approaches were used to enhance the ADCC efficacy: random mutagenesis of 
CD96-V-genes, and Fc-engineering. The CD96 mini-antibody with mutated-scFv, 
and an engineered-IgG1-Fc variant (CD96-S32F-scFv-Fc-IgG1-eng), proved to be 
more effective in mediating tumor cell lysis, compared to other formats of this 
antibody. The CD96 mini-antibody with wild type scFv and an engineered-IgG1-Fc 
variant (CD96-wt-scFv-IgG1-Fc-eng), also showed significantly higher ADCC activity 
compared to the CD96 mini-antibody with wild type scFv, and wild type IgG1-Fc 
(CD96-wt-scFv-IgG1-Fc). In conclusion, these data proved that ADCC could be 
triggered by CD96-specific antibodies. This triggering was improved by antibody 
engineering. Further experiments can demonstrate whether CD96 mini-antibodies 
are able to eliminate AML leukemic stem cells.   
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